RESEARCH

Open Access

Influence of genetic polymorphism on sports talent performance versus non-athletes: a systematic review and meta-analysis



Cirley Pinheiro Ferreira^{1,2*}[®], Valmir Oliveira Silvino^{1,2}[®], Rebeca Gonçalves Trevisano³[®], Rayane Carvalho de Moura¹[®], Sandro Soares Almeida^{4,5,6}[®] and Marcos Antonio Pereira dos Santos^{1,2}[®]

Abstract

Background Talented athletes exhibit remarkable skills and performance in their respective sports, setting them apart from their peers. It has been observed that genetic polymorphisms can influence variations in sports performance, leading to numerous studies aimed at validating genetic markers for identifying sports talents. This study aims to evaluate the potential contribution of genetic factors associated with athletic performance predisposition in identifying sports talents.

Methods A systematic review was conducted following the PRISMA framework, utilizing the PICO methodology to develop the research question. The search was limited to case-control studies published between 2003 and June 2024, and databases such as Medline, LILACS, WPRIM, IBECS, CUMED, VETINDEX, Web of Science, Science Direct, Scopus and Scielo were utilized. The STREGA tool was employed to assess the quality of the selected studies.

Results A total of 1,132 articles were initially identified, of which 119 studies were included in the review. Within these studies, 50 genes and 94 polymorphisms were identified, showing associations with sports talent characteristics such as endurance, strength, power, and speed. The most frequently mentioned genes were ACTN3 (27.0%) and ACE (11.3%).

Conclusion The ACE I/D and ACTN3 R577X polymorphisms are frequently discussed in the literature. Although athletic performance may be influenced by different genetic polymorphisms, limitations exist in associating them with athletic performance across certain genotypes and phenotypes. Future research is suggested to investigate the influence of polymorphisms in elite athletes from diverse backgrounds and sports disciplines.

Keywords Athletic performance, Elite athletes, Genetic polymorphisms, sports talents

*Correspondence:

Cirley Pinheiro Ferreira

cirley.prof@gmail.com

¹Department of Biophysics and Physiology, Nucleus of Study in Physiology Applied to Performance and Health, Federal University of Piauí, 685 Odilon Araújo Avenue, Piçarra, Teresina, PI 64017-280, Brazil



²Northeast Biotechnology Network (RENORBIO) postgraduate program, Teresina, Brazil

³Department of Obstetrician, Paulista School of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil ⁴Hospital Israelita Albert Einstein, São Paulo, SP, Brazil ⁵Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil ⁶Anhanguera College of Guarulhos, Guarulhos, SP, Brazil

© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creative.commons.org/licenses/by-nc-nd/4.0/.

Introduction

The term sports talent has been used to describe individuals who express aptitude for excellence in physical performance in certain sports [1]. Being a talent requires not only dedication, determination, specialized training, nutrition and favorable environmental factors from the athlete, but also is affected by maturational [2], psychological [3], and genetics [4] factors. In fact, genetics has been pointed out as partially responsible for the physical, anthropometric or physiological characteristics necessary for athletic excellence [5, 6].

The influence of genetics and its mechanisms on sports performance have been extensively researched worldwide, in an attempt to use genetic information as predictors of elite status [7]. Genetic polymorphisms are well known for affecting protein expression, thereby potentially influencing an individual's physical abilities, athletic performance, and response to exercise [8]. Among the polymorphisms associated with the performance of elite athletes, we can mention the α -actinin-3 (ACTN3) R577X and angiotensin converting enzyme (ACE) I/D (endurance and power) [9], bradykinin receptor B2 (BDKRB2) (endurance) [10], angiotensinogen (AGT) M235T (rs699) (strength and power) [11, 12], nuclear respiratory factor 2 (NRF-2) intron 3 A/G (endurance) [13, 14], as well as nitric oxide synthase 3 (NOS3) Glu-298Asp (rs1799983) and adenosine monophosphate deaminase 1 (AMPD1) Gln45Ter (rs17602729) (resistance) [15].

Studies indicate that genetic factors account for 44-68% of the phenotypic variability [7, 16]. Genetic elements have great influence on athletic performance components such as endurance, strength, power and other important characteristics in sport [12, 17]. However, despite the existence of studies supporting these findings, numerous genetic variants and the underlying mechanisms of their effects remain unknown [18]. Due to this lack of knowledge, it is worrying to know the existence of an emerging market of direct-to-consumer genetic tests that aim to identify athletic talents in children [19], focusing mainly on ACTN3 and ECA genes, due to the greater volume of research on these polymorphisms since 2015 [20]. Thus, the objective of the present meta-analysis was to assess whether the potential genetic factors identified as predictors of athletic performance can aid in identifying sports talents.

Methods

Search strategy

This systematic review was conducted in accordance with the framework provided by PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement) [21] and was registered with PROSPERO (CRD42022311044) on March 18, 2022. A literature search was conducted by two independent researchers using Scielo, BVS (Medline, LILACS, WPRIM, IBECS, CUMED, VETINDEX), Web of Science, Science Direct, and Scopus databases, covering the period from 2003 to June 2024. The review used a research question developed with the PICO methodology [22], in which the population was elite athletes or sport talents, the intervention was genetic polymorphisms, the comparator was control or non-athlete, and the outcome was athletic or sports performance. The guiding question used in this study was: Can genetic polymorphisms influence athletic performance of sports talents compared to controls or non-athletes?

Keywords used for the search included the following: "elite athletes, "professional athletes", "sports performance", "genetic fitness" and "polymorphism". Descriptors were obtained from the Health Sciences Descriptors (DeCS) and Medical Subject Headings (MeSH) and related keywords, combined with the Boolean operators "AND" and "OR".

Inclusion and exclusion criteria

Articles were included if they met the following five criteria: (one) case control design, (two) with athletes of any age or sex, (three) associated with athletic performance (strength, speed, endurance and power), (four) written in English language and (five) be published in the last 20 years. Studies that did not meet the inclusion criteria, involving animals, repeated studies, placebo-controlled studies, cell studies, thesis, dissertations, abstracts, not available in full and that did not answer the guiding question were excluded from this review.

Case-control articles, including polymorphisms associated with sports performance (strength, endurance, speed and power) of elite athletes were included in the study. On the other hand, studies that contained unclear data did not include a control group, and those whose full text could not be available were excluded from this meta-analysis.

Data extraction

The search of the articles was performed by two reviewers (C.P.F. and V.O.S.). Independently, each author analyzed the title and abstract of the studies found in the databases. The files resulting from the search were sent to the Rayyan Systematic Review Online Data Management Platform, for exclusion of duplicate and screening of the articles. Then, the articles included after the screening were analyzed in full, in accordance with the eligibility criteria. Data from published studies were extracted according to the following characteristics and numbers: first author, year of publication, gene (full name), polymorphism, objective of the study, results, study design, groups, number of subjects (sex), age (years), and nationality of the athletes. In case of conflict of decision during the selection of articles, a third reviewer was consulted (M.A.P.S.).

Quality assessment

The methodological quality of the studies was determined by two independent reviewers (C.P.F. and R.C.M.), according to the Strengthening the Reporting of the Genetic Association (STREGA) guidelines for casecontrol studies [23]. The STREGA statement represents an extension of Strengthening the Reporting of Observational Studies in Epidemiology (STROBE). 40 items from the STROBE checklist were analyzed following the guidelines by the STREGA declaration. After the evaluation of the items, a total score of 0 to 40 was reported for each article. The studies were rated as: A - High quality (30 to 40 points), B - Moderate quality (20 to 29 points) and C - Low quality (0 to 19 points). For each item, there are 2 scores: "yes" (score 1) or "no" (score 0). Discrepancies between reviewers were resolved by consensus and, in case of persistent disagreement, the evaluation was performed by a third reviewer (M.A.P.S.). The STROBE quality scoring system proposed by Liu et al. [24] was modified and used in this study.

Statistical analysis

The statistical analysis involved the grouping of data from the included studies. The publication bias was evaluated by funnel graphs. The effect size was calculated as the risk ratio, followed by 95% confidence intervals. In this study, using a case-control design, we examined the polymorphism distributions of ACE I/D and ACTN3 R577X or rs1815739 among elite athletes and healthy control subjects. Statistical analysis of the frequencies of polymorphism between groups (athletes and controls) was performed using R Studio 4.2.3 (RStudio, PBC, Boston, MA), supported by R version 4.0.0 (The R Foundation, Vienna, Austria). The evaluation of frequencies by polymorphism between groups was determined via metacont function, considering ID+DD and II for ACE and RR+RX and XX for ACTN3.

Results

The systematic search yielded a total of 180 articles, which were then subjected to full reading. Among them, 119 articles were included for the purpose of conducting a systematic review, while 53 articles were included in the meta-analysis. The publication dates of the selected studies spanned from 2003 to 2024. The selection process of this study is depicted in Fig. 1.

The characteristics of the 119 studies included in this review are summarized in Table 1. A total of 50 genes and 94 different polymorphisms were investigated. The most frequent genes were ACTN3 and ACE, representing 27.0% (n=43) and 11.3% (n=18) of the sample, respectively. Among the 94 polymorphisms cited, ACTN3 R577X=rs1815739 and ACE I/D were the most frequent with 22.4% (n=43) and 9.4% (n=18), respectively.

All studies presented in this review are case-control. 77,690 participants were analyzed, of which 32,198 were athletes and 45,492 were non-athlete controls. As for the description of sex, 107 articles showed that 75.2% (n=20,998) of the athletes were men and 24.8% (n=6,933) were women, 5 articles did not mention the number of athletes and controls by sex and 7 articles described only partially. The studies included participants expert in strength, power, speed and endurance sport disciplines. Considering the nationality of the participants (athletes and controls), the majority were Polish (20.0%), followed by Israeli (16.6%), Russian (11.7%) and Spanish (10.3%), as shown in Table 2.

The quality evaluation showed that 89.1% (n=106) of the studies had grade A (high quality) and 10.9% (n=13) grade B (medium quality), according to the STREGA [23] as shown in Table 3. Therefore, the studies are adequate for this review as they met the quality expected for the investigation.

However, it is important to highlight that all the studies analyzed had methodological limitations, specifically concerning sample size calculation. The absence of sample size calculation in the original studies can bias the true effect of the investigated associations. Studies indicate that when sample size calculation is not performed, the results regarding power, effect size, and reproducibility are directly affected [25, 26] (Andrade, 2020; Serdar et al., 2020). Therefore, despite the quality of the studies included in the sample, it is important to assess this limitation, considering that even well-executed studies may fail to adequately address the research question. The results of Tables 1 and 2, and 3 can be found in the supplementary material 1 (S1).

Regarding the meta-analysis, we evaluated the data regarding the genotypic frequency and total number of participants available in the original articles. We aimed to determine whether there was a predominance of any genetic profile between athletes and non-athletes, based on the frequency of ACE (DD+ID vs. II) and ACTN3 (RR+RX vs. XX) genotypes. Polymorphisms were selected due to their presence in a larger number of studies included in this review. The frequencies of the DD and ID genotypes for the ACE and the RR and RX genotypes for the ACTN3 were combined in order to improve the graphical visualization of the analysis in the forest plot, which mainly took into consideration the frequency of genotypes among the groups of cases and controls. This approach was adopted in accordance with a previous investigation [58].




Fig. 1 Study selection PRISMA flow diagram Source: Developed by the authors

The meta-analysis found no significant difference comparing athletes and controls regarding the RR+RX (Fig. 2) and XX (Fig. 3) polymorphisms of the ACTN3. Similarly, there was no significant difference between athletes and controls regarding the II and the DD+ID polymorphisms of the ACE gene (Fig. 4). The Egger's test was performed to provide statistical evidence of funnel plot asymmetry. The results indicated publication bias for the performed analysis (p < 0.10) regarding the ACTN3

RR (Fig. 5, Panel A), ACTN3 RR+RX (Fig. 5, Panel B), ACE II (Fig. 5, Panel C), and ACE DD+ID (Fig. 5, Panel D), polymorphisms. It is worth mentioning that the asymmetry of the ACE gene (Fig. 5, Panels C and D) is more evident.

	Experim	nental	С	ontrol				Weight	Weight
Study	Events	Total	Events	Total	Risk Ratio	RR	95%-CI	(common)	(random)
Ahmetov et al. (2010)	429	456	1035	1211		1.10	[1.07; 1.14]	6.5%	3.9%
Akazawa et al. (2022)	683	906	478	649		1.02	[0.96; 1.09]	6.4%	3.3%
Ben-Zaken et al. (2015c)	217	278	177	217		0.96	[0.88; 1.05]	2.3%	2.6%
Ben-Zaken et al. (2019)	99	125	72	86		0.95	[0.83; 1.08]	1.0%	1.8%
Chiu et al. (2011)	140	168	485	603	- <u> </u>	1.04	[0.96; 1.12]	2.4%	2.8%
De Albuquerque-Neto et al. (2024)	91	123	365	448		0.91	[0.81; 1.02]	1.8%	2.1%
Djarova et al. (2013)	4	5	62	72		0.93	[0.59; 1.45]	0.1%	0.2%
Dogan et al. (2022)	99	131	78	89		0.86	[0.76; 0.98]	1.1%	1.9%
Döring et al. (2010)	242	305	241	292		0.96	[0.89; 1.04]	2.8%	2.8%
Druzhevskaya et al. (2008)	456	486	1026	1197		1.09	[1.06; 1.13]	6.8%	3.9%
Eynon et al. (2009a)	120	155	198	240		0.94	[0.85; 1.04]	1.8%	2.3%
Eynon et al. (2010a)	114	155	198	240		0.89	[0.80; 1.00]	1.8%	2.1%
Eynon et al. (2012)	548	633	682	808	+	1.03	[0.98; 1.07]	6.8%	3.7%
Evnon et al. (2014)	763	888	489	568	÷	1.00	[0.96; 1.04]	6.8%	3.7%
Garatachea et al. (2014)	46	60	173	216		0.96	[0.82; 1.12]	0.9%	1.4%
Gineviciene et al. (2011)	168	193	224	250		0.97	[0.91; 1.04]	2.2%	3.1%
Gineviciene et al. (2016)	143	161	1048	1202			[0.96; 1.08]	2.8%	3.3%
Ginszt et al. (2018)	84	100	83	100			[0.89; 1.14]	0.9%	1.9%
Grover et al. (2020)	15	23	16	25			[0.67; 1.55]	0.2%	0.3%
Gunel et al. (2014)	24	37	33	37 -	_		[0.56; 0.95]	0.4%	0.6%
Hong et al. (2013)	128	150	296	361	_ <u></u>		[0.96; 1.13]	2.0%	2.7%
Hwang et al. (2019)	89	111	113	145			[0.91; 1.17]	1.1%	1.8%
Itaka et al. (2016)	104	156	878	1191			[0.81; 1.02]	2.3%	2.0%
Kikuchi et al. (2013)	106	135	172	243	÷		[0.98; 1.25]	1.4%	1.9%
Kikuchi et al. (2016)		1057	591	810	<u> </u>		[0.97; 1.08]	7.7%	3.4%
Li et al. (2017)	163	198	168	206	<u> </u>		[0.92; 1.11]	1.9%	2.5%
Lucia et al. (2006)	80	102	101	123	_		[0.84; 1.09]	1.0%	1.8%
Massidda et al. (2015)	158	178	167	190			[0.94; 1.09]	1.8%	2.9%
Meckel et al. (2020)	51	60	42	51			[0.87; 1.22]	0.5%	1.3%
Mikami et al. (2014)	237	299	478	649			[1.00; 1.16]	3.4%	2.9%
Min et al. (2021)	48	56	183	221			[0.92; 1.17]	0.8%	1.9%
Moreno-Perez et al. (2020)	46	62	56	72			[0.79; 1.16]	0.6%	1.0%
Orysiak et al. (2014)	176	200	316	354	<u>P</u>		[0.93; 1.05]	2.6%	3.2%
Orysiak et al. (2015)	138	172	316	354			[0.83; 0.98]	2.4%	2.7%
Papadimitriou et al. (2008)	113	135	148	181			[0.93; 1.13]	1.4%	2.3%
Rodríguez-Romo et at. (2013)	83	108	281	343			[0.84; 1.05]	1.5%	2.0%
Ruíz et al. (2011)	57	66	273	334			[0.95; 1.18]	1.0%	2.2%
Ruíz et al. (2013)	290	361	281	343			[0.91; 1.05]	3.3%	3.0%
Shang et al. (2010)	209	250	374	450	E		[0.94; 1.08]	3.1%	3.1%
Wei (2021)	114	114	168	200			[1.12; 1.26]	1.4%	3.3%
Yamak et al. (2015)	117	150	131	150	_ _		[0.80; 0.99]	1.5%	2.2%
Yang et al. (2017)	86	103	33	50	·		[1.02; 1.57]	0.5%	0.9%
Yang et al. (2023)	97	142	69	107			[0.88; 1.27]	0.9%	1.2%
,	01				4 4 4				
Common effect model		9753		15678	þ		[1.00; 1.02]	100.0%	
Random effects model					¢	1.00	[0.98; 1.03]		100.0%
Heterogeneity: $I^2 = 68\%$, $\mathbf{t}^2 = 0.0031$,	p < 0.01								
					0.75 1 1.5				

Fig. 2 Forest plot of the meta-analysis comparing the frequency of RR+RX (ACTN3 polymorphism) genotypes in athletes (experimental) and nonathletes (controls)

Discussion

The objective of this systematic review was to evaluate the potential contribution of genetic factors, which are commonly associated with athletic performance, in identifying sports talents. The comprehension of genetic variations linked to sports performance can offer valuable insights for the detection, selection, and development of individuals with exceptional athletic abilities. Moreover, by gaining a better understanding of the impact of specific polymorphisms and their underlying mechanisms, it becomes possible to optimize individual training programs. This optimization aims to positively influence physical performance and potentially compensate for any unfavorable environmental or genetic factors.

In this review, we have compiled a list of genetic markers that have the potential to influence the physical performance of athletes in various categories, including endurance, power, speed, and strength. During the metaanalysis, we specifically investigated the variations in frequencies of ACE and ACTN3 polymorphisms among athletes and control groups. We considered different sports categories, sexes, ages, and ethnicities to provide a

Study	Experim Events		C Events	ontrol Total	Risk Ratio	RR	95%-CI	Weight (common)	Weight (random)
Ahmetov et al. (2010)	27	456	176	1211	= 1	0 41	[0.28; 0.60]	4.8%	2.7%
Akazawa et al. (2022)	223	906	171	649	+		[0.79; 1.11]	9.9%	3.9%
Ben-Zaken et al. (2015c)	61	278	40	217	1		[0.83; 1.70]	2.2%	2.9%
Ben-Zaken et al. (2019)	26	125	14	86	4-		[0.71; 2.30]	0.8%	1.8%
Chiu et al. (2011)	28	168	118	603	+		[0.59; 1.24]	2.6%	2.8%
De Albuquerque-Neto et al. (2024) 32	123	83	448	-		[0.98; 2.00]	1.8%	2.9%
Djarova et al. (2013)	́1	5	10	72	<u></u>	1.44	[0.23; 9.11]	0.1%	0.3%
Dogan et al. (2022)	32	131	11	89	<u> </u>	1.98	[1.05; 3.71]	0.7%	1.7%
Döring et al. (2010)	63	305	51	292	+	1.18	[0.85; 1.65]	2.6%	3.0%
Druzhevskaya et al. (2008)	30	486	171	1197	-	0.43	[0.30; 0.63]	4.9%	2.8%
Eynon et al. (2009a)	35	155	42	240	1	1.29	[0.86; 1.93]	1.6%	2.6%
Eynon et al. (2010a)	41	155	42	240	*	1.51	[1.03; 2.21]	1.6%	2.7%
Eynon et al. (2012)	85	633	126	808		0.86	[0.67; 1.11]	5.5%	3.4%
Eynon et al. (2014)	125	888	79	568	÷	1.01	[0.78; 1.31]	4.8%	3.4%
Garatachea et al. (2014)	14	60	43	216		1.17	[0.69; 1.99]	0.9%	2.0%
Gineviciene et al. (2011)	25	193	26	250			[0.74; 2.09]	1.1%	2.1%
Gineviciene et al. (2016)	18	161	154	1202	+		[0.55; 1.38]	1.8%	2.3%
Ginszt et al. (2018)	16	100	17	100	+		[0.50; 1.76]	0.8%	1.7%
Grover et al. (2020)	8	23	9	25			[0.45; 2.08]	0.4%	1.3%
Gunel et al. (2014)	13	37	4	37	<u>↓</u>		[1.17; 9.05]	0.2%	0.8%
Hong et al. (2013)	22		65	361			[0.52; 1.27]	1.9%	2.4%
Hwang et al. (2019)	22	111	32	145	+		[0.55; 1.46]	1.4%	2.2%
Itaka et al. (2016)	52	156	313	1191	ت		[1.00; 1.61]	3.6%	3.5%
Kikuchi et al. (2013)	29	135	71	243			[0.50; 1.07]	2.5%	2.7%
Kikuchi et al. (2016)	269		219	810	+		[0.81; 1.10]	12.3%	4.0%
Li et al. (2017)	35	198	38	206	Ť		[0.63; 1.45]	1.9%	2.5%
Lucia et al. (2006)	22		22	123			[0.71; 2.05]	1.0%	2.0%
Massidda et al. (2015)	20	178	23	190	1		[0.53; 1.63]	1.1%	1.9%
Meckel et al. (2020)	9	60	9	51			[0.37; 1.98]	0.5%	1.1%
Mikami et al. (2014)	62	299 56	171	649			[0.61; 1.02]	5.4%	3.4%
Min et al. (2021) Marana, Báraz et al. (2020)	8 16	56 62	38 16	221			[0.41; 1.68]	0.8%	1.4%
Moreno-Pérez et al. (2020)	24	200	38	72 354	T		[0.63; 2.12]	0.7% 1.4%	1.7% 2.2%
Orysiak et al. (2014)		172	30	354 354	T.		[0.69; 1.81]	1.4%	2.2%
Orysiak et al. (2015) Papadimitriou et al. (2008)	34 22	135	33	354 181	1		[1.20; 2.82] [0.55; 1.46]	1.2%	2.5%
Rodríguez-Romo et at. (2008)	22	108	62	343	1		[0.85; 1.93]	1.4%	2.2%
Ruíz et al. (2011)	25	66	61	343 334			[0.39; 1.43]	1.0%	2.6%
Ruíz et al. (2013)	71	361	62	343	1		[0.80; 1.43]	3.2%	3.1%
Shang et al. (2010)	41	250	76	450	I		[0.69; 1.37]	2.7%	2.9%
Wei (2021)	41	114	32	200 ·	Ī		[0.09; 1.37]	1.2%	0.1%
Yamak et al. (2015)	33	150	32 19	150			[1.04; 2.91]	0.9%	2.1%
Yang et al. (2017)	17	103	19	50			[0.27; 0.87]	1.1%	1.8%
Yang et al. (2023)	45	142	38	107	1		[0.63; 1.27]	2.2%	2.9%
rang 5t al. (2020)	40	142	50	107	1	0.09	[0.00, 1.27]	2.2/0	2.370
Common effect model		9753		15678			[0.90; 1.01]	100.0%	
Random effects model						1.00	[0.90; 1.11]		100.0%
Heterogeneity: $I^2 = 60\%$, $\mathbf{T}^2 = 0.0641$,	p < 0.01								
					0.01 0.1 1 10 100				

Fig. 3 Forest plot of the meta-analysis comparing the frequency of the XX genotype of ACTN3 polymorphism in athletes (experimental) and nonathletes (controls)

comprehensive analysis. The selection of these two polymorphisms was based on the abundance of data available from the articles included in this review, ensuring a robust analysis of their potential impact on athletic performance. Our aim was to conduct a comprehensive and rigorous analysis of the association between these polymorphisms and athletic performance. However, due to the heterogeneity in the data available from the included studies, we were unable to evaluate specific factors such as BMI, strength, and respiratory capacity parameters. Additionally, when analyzing the frequencies of ACE polymorphisms (ID+DD vs. II) and ACTN3 (RR+RX vs. XX), we did not find statistically significant differences between the groups of athletes and controls, as illustrated in Figs. 2 and 3, and 4.

The role of genetic polymorphism in determining athletic performance is widely recognized [27]. Innate factors play a key role in sports performance and related phenotypes such as power, strength, aerobic capacity, flexibility and coordination [28]. However, the search for genetic variants that may confer a greater predisposition to athletic success, taking into account the diversity of

Polymorphism ACE II	Experim	ental	Co	ontrol				Weight	Weight
Study			Events		Risk Ratio	RR	95%-CI	(common)	•
	45	400		0.47	1-	4.40	10.05.0.401	0.00/	0.00/
Amir et al. (2007)	15	120	26	247			[0.65; 2.16]	2.3%	2.3%
Ash et al. (2011)	16	114	24	315			[1.02; 3.34]	1.7%	2.3%
Collins et al. (2004)	59	272	97	447			[0.75; 1.33]	10.0%	8.7%
De Albuquerque-Neto et al. (2024)	42	123	239	710	+	1.01	[0.78; 1.32]	9.7%	9.7%
Djarova et al. (2013)	1	5	8	72		1.80	[0.28; 11.69]	0.1%	0.2%
Eider et al. (2013)	13	100	74	354		0.62	[0.36; 1.07]	4.5%	2.7%
Falahati and Arazi (2019)	7	29	6	28		1.13	[0.43; 2.94]	0.8%	0.9%
Gineviciene et al. (2011)	50	193	59	250	- <u>-</u>	1.10	[0.79; 1.52]	7.0%	7.0%
Gineviciene et al. (2012)	47	199	41	167	-+	0.96	[0.67; 1.39]	6.1%	5.7%
Gineviciene et al. (2016)	49	161	298	1202		1.23	[0.95; 1.58]	9.6%	10.5%
Gunel et al. (2014)	3	37	12	37	.	0.25	[0.08; 0.81]	1.6%	0.6%
Hwang et al. (2019)	41	111	47	145	-	1.14	[0.81; 1.60]	5.6%	6.6%
Kim et al. (2010)	64	155	460	931		0.84	[0.69; 1.02]	18.0%	15.0%
Scott et al. (2005)	44	291	12	85	 _	1.07	[0.59; 1.93]	2.5%	2.4%
Shahmoradi et al. (2014)	36	156	27	163	- <u>-</u>	1.39	[0.89; 2.18]	3.6%	4.0%
Tobina et al. (2010)	19	37	155	335	_ <u>_</u>	1.11	[0.79; 1.55]	4.2%	6.7%
Wei (2021)	24	60	84	200		0.95	[0.67; 1.35]	5.3%	6.2%
Yang et al. (2023)	59	142	46	107	<u>+</u>	0.97	[0.72; 1.30]	7.2%	8.4%
Common effect model		2305		5795	\$	1.01	[0.93; 1.10]	100.0%	
Random effects model					\$	1.02	[0.93; 1.12]		100.0%
Heterogeneity: $I^2 = 23\%$, $\mathbf{t}^2 = 0.0048$,	p = 0.18								
· · · · · · · · · · · · · · · · · · ·					0.1 0.5 1 2 10				

Polymorphism ACE DD+ID	Experim	ental	Co	ontrol				Weight	Weight
Study			Events		Risk Ratio	RR	95%-CI	(common)	•
Amir et al. (2007)	105	120	221	247		0.98	[0.90; 1.06]	7.1%	10.7%
Ash et al. (2011)	98	114	291	315		0.93	[0.86; 1.01]	7.6%	10.7%
Collins et al. (2004)	213	272	350	447		1.00	[0.92; 1.08]	13.1%	10.9%
De Albuquerque-Neto et al. (2024)	81	123	471	710		0.99	[0.87; 1.14]	6.9%	5.1%
Djarova et al. (2013)	4	5	64	72	· · · · · ·	0.90	[0.58; 1.41]	0.4%	0.6%
Eider et al. (2013)	87	100	280	354		1.10	[1.00; 1.21]	6.1%	9.0%
Falahati e Arazi (2019)	22	29	22	28		0.97	[0.73; 1.28]	1.1%	1.4%
Gineviciene et al. (2011)	143	193	191	250		0.97	[0.87; 1.08]	8.2%	7.3%
Gineviciene et al. (2012)	152	199	126	167	- <u>+</u>	1.01	[0.90; 1.14]	6.8%	6.6%
Gineviciene et al. (2016)	112	161	904	1202		0.92	[0.83; 1.03]	10.6%	7.4%
Gunel et al. (2014)	34	37	25	37		- 1.36	[1.07; 1.73]	1.2%	1.9%
Hwang et al. (2019)	70	111	98	145		0.93	[0.78; 1.12]	4.2%	3.2%
Kim et al. (2010)	91	155	471	931		1.16	[1.00; 1.34]	6.6%	4.6%
Scott et al. (2005)	247	291	73	85		0.99	[0.90; 1.09]	5.6%	8.3%
Shahmoradi et al. (2014)	120	156	136	163		0.92	[0.83; 1.03]	6.6%	7.1%
Tobina et al. (2010)	18	37	180	335		0.91	[0.64; 1.28]	1.8%	1.0%
Wei (2021)	36	60	116	200		1.03	[0.82; 1.31]	2.6%	2.0%
Yang et al. (2023)	83	142	61	107		1.03	[0.83; 1.27]	3.4%	2.4%
Common effect model		2305		5795	4	0.99	[0.96; 1.03]	100.0%	
Random effects model					4		[0.96; 1.03]		100.0%
Heterogeneity: $I^2 = 26\%$, $\mathbf{T}^2 = 0.0013$,	p = 0.15								
, , ,					0.75 1 1.5				

Fig. 4 Forest plot of the meta-analysis comparing the frequency of the II and DD+ID ACE polymorphisms in athletes (experimental) and non-athletes (controls)

sports modalities, has not yet been adequately replicated [7, 12].

Athletic status, regardless of the type of sport, is influenced by several factors, including heredity [29]. Height, which plays a crucial role in the success of some sports, is estimated to account for approximately 80% of the variation attributed to genetic factors [4]. Likewise, the body type (mesomorphic or ectomorphic) is highly influenced by heritability [30]. However, there is still a gap in knowledge about the specific genetic variants that contribute to physical performance. Further studies to elucidate this scenario and provide a more comprehensive understanding of the genetic factors involved in athletic performance are suggested.

ACTN3 and ACE polymorphisms and athlete performance

In our review, we observed that, of the 50 genes mentioned, 27.0% (*n*=43) referred to ACTN3 and 11.3%




Fig. 5 Funnel plot of risk ratio versus standard error for the ACTN3 XX (Panel A), ACTN3 RR+RX (Panel B), ACE II (Panel C), ACE DD+ID (Panel D), polymorphisms

(n=18) mentioned ACE. Regarding these genes, several studies have been conducted their influence on physical performance [31–34], as they affect phenotypic characteristics related to athletic performance [32–35]. In humans, the ACTN3 gene is expressed primarily in type II skeletal muscle fibers, which are associated with explosive muscle contractions and strength [36]. ACE, on the other hand, is involved in the regulation of circulatory homeostasis, in growth of skeletal muscles, and cardiovascular functions [37].

The R577X polymorphism of ACTN3 presents three genotypes. The RR and RX, which express the α -actinin-3 protein, and the XX, which is deficient of that protein [38]. The XX genotype has been frequently associated with resistance phenotype [39, 40], while RR has been more frequent in speed, power and strength athletes [41]. The ACE I/D gene polymorphism has two alleles, namely I (insertion) and D (deletion), which compose the genotypes II, ID and DD. In general, the I allele seems to be associated with endurance sports and the D with power-oriented sports [3, 42].

Several studies have been conducted to examine the influence of the ACTN3 XX genotype on athletic performance in endurance sports [43, 44]. Polish canoe athletes in endurance events (1000 m) were reported to be 2.95 times more likely to have the XX genotype than non-athletic controls [45]. Brazilian swimmers are 1.79 times more likely to belong to the athlete group compared to the control group (p=0.04) [46]. Israeli long-distance runners had a higher prevalence of the XX genotype when compared to control groups, short-distance runners, and short- and long-distance swimmers [47].

When analyzing the frequency of ACTN3 R577X polymorphisms in an Israeli population, it was found that the XX genotype is significantly more prevalent in endurance athletes compared to controls (p=0.02) and sprinters (p=0.002), indicating that the XX genotype and the X allele may not be critical but rather additive for endurance performance [48]. The chances of an endurance athlete harboring the XX genotype are 1.88 times higher (95% CI: 1.07–3.31; p=0.028) compared to power athletes with the RR genotype [49].

According to Lucia et al. [50], the literature indicates that the ACTN3 XX polymorphism may confer some advantage in endurance events. Their study with professional Spanish endurance cyclists showed a trend toward a higher frequency of the XX genotype compared to controls, although this difference did not reach statistical significance. The study highlighted a limitation in the small sample size, suggesting the need for future studies with larger samples to increase the statistical power of comparisons between groups.

Yamak et al. [51] also observed a higher frequency of the XX genotype in athletes from nine sports (soccer, basketball, athletics, volleyball, handball, judo, wrestling, taekwondo, rugby) living in the Black Sea region, although no significant difference was found in the distribution when compared to the control group. Similarly, Döring et al. [52] did not find a significant association with endurance performance.

When associating the ACTN3 R577X polymorphism with power status in various sports among Russian athletes, the frequencies of the XX genotype (P<0.0001) and the X allele (P=0.004) were significantly lower in power-oriented athletes compared to controls [53].

Results from a study involving a rowing competition (endurance-oriented athletes) showed that the frequencies of the ACTN3 577XX genotype and the 577X allele were significantly lower in endurance-oriented athletes compared to controls [54]. The presence of this genotype appears to be detrimental to the speed and power performance of athletes [55]. Additionally, according to Hong and Jin [56], the effect of the XX genotype in Korean endurance/power athletes may be influenced by sex. The ACTN3 X allele in Chinese runners appears to provide an advantage in endurance performance for female athletes but not for male athletes [57]. Additionally, a significant association was found between the X allele and endurance performance levels in Polish athletes across various sports including 3,000 m to marathon running, cross-country skiing, speed skating (3,000–10,000 m), swimming (400–1,500 m), modern pentathlon, orienteering, biathlon, mountain biking, road cycling, triathlon, and rowing (Olympic, world-class, or national level) [3].

Murtagh et al. [58] investigated different genes, including ACTN3, to determine the maturity status of soccer players by comparing their genetic profile, associated with power and speed performance, according to the predicted age at peak-height-velocity (PHV). They revealed that the frequency of the ACTN3 XX genotype was higher in athletes in the predicted pre-PHV compared to controls. This is due to the fact that the XX homozygote does not produce the structural alpha-actinin-3 protein.

In elite athletes from Lithuania, the ACTN3 X allele has been shown to influence speed and power performance, with those carrying the XX and RX genotypes having greater potential to achieve better results in power-demanding sports [59]. Contrary to these findings, a study involving two Bulgarian mountaineers who reached the summit of Mount Everest revealed that the frequency of the X allele is more predominant in endurance athletes [60].

Considering power performance among elite athletes, the RR genotype of ACTN3 has been overrepresented in European power/sprint athletes (Polish, Russian, and Spanish) [61], more frequent in Israeli sprinters and jumpers [32], and in Greek track and field athletes [62].

Studies examining the relationship between the R577X (rs1815739) polymorphism of ACTN3 and strength performance have indicated associations with lower limb explosive strength in young male Polish athletes [63], long jump and vertical jump performance in Chinese sprint/power athletes [55], middle to long-distance swimming performance (\geq 400 m, \leq 1,500 m) in Chinese athletes, particularly among female swimmers [64], climbing in European athletes (Poland, Russia, Austria) [31], running and jumping in Israeli athletes [32], and hand grip strength in Korean male combat athletes [34].

Dogan et al. [65] indicated that the RR genotype of the ACTN3 gene was more prevalent in both sprinters and long-distance athletes, suggesting that this genotype could serve as a potential biomarker for personalized training programs. On the other hand, Eynon et al. [66] showed that the interaction between the RR genotype of ACTN3+HIF1A Pro/Pro in Israeli individuals is more frequent in sprint athletes compared to endurance athletes and the control group.

The ACTN3 R577X polymorphism appears to have no influence on explosive power performance in elite volleyball players from Spain [67]. According to Moreno-Perez et al. [68], it was not possible to support the hypothesis that the ACTN3 RR genotype would be more frequent in professional players. The authors found that the distribution of the RR, RX, and XX genotypes were statistically similar between professional and non-professional Spanish tennis players. Similarly, regarding national-level Israeli soccer players, no association was found in the frequency of the RR genotype when compared to nationallevel long-distance runners or sprinters/jumpers [69].

The R allele, responsible for the expression of the ACTN3 protein in fast glycolytic muscle fibers, has shown higher frequencies in Indian power/speed athletes [30], associated with sprint performance in Israeli international-level track and field athletes [48], speed performance in international Taiwanese swimmers [70], strength and power events in Chinese soccer players [71], sports requiring greater muscular strength [72], and power performance in Brazilian athletes [73] compared to controls. Additionally, it was significantly overrepresented in elite Chinese female soccer players compared to controls [37].

When evaluating Japanese track and field athletes, the frequency of the RR+RX genotype of the ACTN3 R577X polymorphism was significantly associated with 100 m sprint (p=0.025) [74] and 100–200 m (p=0.003) [75] performances when compared to the control groups. Additionally, the R allele has been associated with hand grip strength (left hand) in male athletes [34] and positively correlated with the athletic status of elite Japanese wrestlers [76].

Of the 43 studies mentioning ACTN3, eight showed no significant association with performance parameters, including explosive lower limb muscle strength in basketball players [77] and Spanish volleyball players [67], strength/power in Russian and Lithuanian athletes [78], athletic performance in Japanese [79] and Spanish athletes [80], athletic performance in Italian football and hockey players [81], athletic performance in Korean athletes across 28 different sports [82], and endurance performance in Caucasian athletes (North American, Finnish, and German) [52].

A study that assessed the polygenic profile to determine sprint and power performance in Japanese track and field athletes found no association between the ACE (rs4340) and ACTN3 (rs1815739) polymorphisms and sprint and power performance [83].

Several studies have been conducted to investigate the relationship between ACE allele frequency and performance in elite athletes. In one study, the ACE D allele was more prevalent in strength performance in Polish athletes [84] as well as endurance performance in Iranian

long-distance cycling athletes [85]. Additionally, the ACE I allele has been suggested to be favorable for endurance sport [86]. However, studies carried out with Brazilian athletes did not find an association between the I allele and endurance performance [73]. Furthermore, the ACE polymorphism did not demonstrate an association with sport performance in a study involving Korean athletes [82].

A study that evaluated genetic profiles associated with cardiorespiratory fitness in Spanish male athletes showed that the frequency of the II genotype or the I allele was lower in elite endurance athletes compared to non-athlete controls [87].

These findings indicate the complexity of the relationship between ACE polymorphism and athletic performance, highlighting the influence of genetic, environmental and ethnic factors in this context.

The ACE I/D polymorphism has been consistently associated with the performance of sprint athletes [43]. Moreover, it was found that the high frequency of the I/D genotype and the I allele was related to the success of Bulgarian climbers in high altitude [60]. However, the same genotype was not associated with cardiovascular determinants such as maximal oxygen consumption $(VO_2 \text{ max})$, and resting heart rate, systolic and diastolic blood pressure in Iranian soccer players. Importantly, that study was limited by the lack of measurement of serum ACE activity and the small sample size [88].

According to Ash et al. [89], no significant differences were observed in the frequency of the ACE genotype ID between endurance athletes and control groups, indicating that this genotype is not a crucial determinant for elite Ethiopian endurance runners. Similarly, Scott et al. [90] concluded that the ACE I/D and A22982G polymorphisms are not strongly associated with elite endurance athlete status among Kenyans.

In Lithuanian athletes, the ID genotype is more frequent compared to controls and is associated with better results in strength and power tests [59]. In another study, Gineviciene et al. [78] concluded that the II genotype of ACE is more favorable for Russian strength/power athletes (OR=1.71; 95% CI: 1.01–2.92; p=0.04), while the ID genotype is preferred among Lithuanian athletes (OR=2.35; 95% CI: 1.10–5.06; p=0.028) [78].

The D allele of the ACE I/D polymorphism is associated with better performance in endurance running among elite Japanese runners [91]. Similarly, the I allele has been associated with endurance performance among top finishers in triathlons in South Africa [92]. Additionally, the D allele of the ACE rs4341 polymorphism has been linked as a positive predictor of athletic performance in high-level Polish athletes [3]. These studies demonstrate that ACE gene polymorphisms influence athletic performance, although this influence may vary depending on the type of sport and the population studied.

The D allele and DD genotype of the ACE I/D polymorphism were overrepresented among elite Israeli marathon athletes, suggesting a possible association between increased ACE activity and the likelihood of being an elite endurance athlete in certain ethnic groups [93]. In contrast, these results were less frequent among highlevel Korean power athletes, with individuals carrying the DD genotype having 3.83 times less success in poweroriented sports compared to those with II+ID genotypes [94].

In a study with Brazilian swimmers, the DD genotype of the ACE gene was more frequent among elite athletes compared to sub-elite athletes, showing a higher likelihood of belonging to the elite group with strength phenotypes [46].

Wei [37] investigated the association between ACE I/D and ACTN3 R577X polymorphisms and performance in Chinese female soccer players. The results revealed that there was no difference in the frequency of ACE I/D genotypes between the athletes vs. control (II 40%, ID 46.7%, DD 13.3% vs. II 42%, ID 48%, DD 10%). However, they found that the combination of ACE and ACTN3 genotypes (II/ID/DD+RR /RX) was a synergistic determinant in their athletic performance, as it was associated with higher VO₂ max values.

Studies that associate ACE I/D and ACTN3 R577X polymorphisms are important because they can guide coaches in selecting the most appropriate exercises and facilitate personalized training based on individuals' genetic characteristics. A study evaluating the effectiveness of different muscular exercises to improve explosive strength, considering ACE and ACTN3 polymorphisms, revealed that individuals with the DD genotype of ACE showed improvements in explosive lower limb strength (measured by the Sargent Test) and sprint speed. On the other hand, individuals with the RR genotype of ACTN3 showed improvements in long jump, the Sargent Test, and power jump. These results indicate that genetics can significantly influence the response to muscle training and improvement in explosive strength variables, highlighting the importance of considering genetic polymorphisms when planning physical training programs [95].

Genetic polymorphisms and resistance performance

In this review, the majority of the studies associated genetic polymorphisms with endurance performance, which can be determined by several factors, including cardiovascular and pulmonary function, muscle metabolism, and musculoskeletal adaptations [93], food intake, VO_2 max, cardiac output [96], body mass or composition [97] or blood lactate levels [98], for instance NRF-2 A/C (rs12594956) [99], ACSL1 (rs6552828) in Chinese [100],

ADRB2 (Arg16Gly) [93, 97], ADRB3 (Trp64Arg) [101] and monocarboxylate transporter 1 (MCT1) A1470T (rs1049434) [102]. In a study with Russian rowers, a higher frequency of the MCT1 A1470T (rs1049434) A allele and AA genotype of was observed in athletes when compared to controls. Furthermore, an association of the MCT1 A1470T polymorphism (rs1049434) with endurance status and blood lactate level after intensive exercise has been shown [98]. On the other hand, the T allele of the MCT1 T1470A polymorphism (rs1049343) was overrepresented in Polish climbers, when compared to the controls [103]. These results indicate the relevance of these genetic polymorphisms in determining endurance performance in different sport disciplines.

The myostatin gene (MSTN), which is expressed in skeletal muscle cells, play a negative role in the regulation of cell growth [18], being considered promising for the treatment of loss of muscle mass [104], bone mineral density and sarcopenia [105], as well as physical performance parameters [106]. Interestingly, the genetic predisposition to gain muscle mass comes from lower MSTN expressions, which benefits the increasing of strength [107]. Thus, this gene has been associated with phenotypic characteristics of not only muscle strength [108, 109] but also endurance performance [110].

Ben-Zaken et al. [106] investigated the MSTN polymorphism (rs1805086) in Israeli runners and swimmers and found a greater frequency of the MSTN 153R allele in elite long and short distance runners of national level. Furthermore, Ben-Zaken et al. [111] showed that the combined frequency of the mutations of MSTN 153Arg(R) and IGF 1245T (rs35767) was significantly greater in endurance runners compared to sprint runners, short- and long-distance swimmers, and controls. However, the authors stated that athletes with the combined IGF-1-MSTN are not guaranteed to have greater benefits in track and field than in swimming. Likewise, Ginevičienė et al. [18] found an association between the MSNT polymorphism (rs11333758) and endurance performance in a cohort of elite Lithuanian athletes. Results revealed that athletes involved in endurance sports, such as marathon, long-distance swimming and rowing, had a 2.1 times greater chance of having the MSTN deletion (-/-) genotype compared to non-athletic individuals (13.6% vs. 0.8%, OR (95% CI) = 2.1 (1.2-3.8), p = 0.001).

The literature points to an interesting finding regarding the gene for the beta-3 subunit of the nicotinic cholinergic receptor (CHRNB3), which plays a role in regulating protein activity in the brain's emotional centers. It has been observed that the G variant of this gene (rs4950) is significantly more frequent in endurance athletes compared to power athletes (p=0.025) [3].

Another polymorphism related to sports performance is BDKRB2 (-9/+9), which plays an important role as an

endothelium-dependent vasodilator [15]. The BDKRB2 -9 allele has been associated with reduced heart rate [10] and improved aerobic endurance in athletes [112]. In our analysis, the BDKRB2 (-9/-9) polymorphism was overrepresented in endurance athletes (Triathletes and Ironman triathletes) compared to male controls [113]. However, our analysis did not confirm these observations in five subsequent studies. Firstly, the allelic and genotypic frequencies of BDKRB2 (-9/+9) showed no significant differences between Polish and Russian athletes compared to controls [114]. In three other studies, variation in the BDKRB2 gene was not associated with swimming performance in well-trained Polish swimmers [115], elite and sub-elite Brazilian swimmers [46], nor with performance in short, medium, or long-distance swimming in Polish athletes of both sexes [116]. Finally, a fifth study found no significant differences among track and field athletes at different competitive levels (national and international) [117].

A study by Hall et al. [96] investigated the association between the PR/SET domain 1 (PRDM1) (rs10499043), glutamate ionotropic receptor NMDA type subunit 3 A (GRIN3A) (rs1535628), and potassium voltage-gated channel subfamily H member 8 (KCNH8) (rs4973706) polymorphisms with VO2 max in runners and rugby players. They observed that runners with the PRDM1 T allele had shorter marathon completion time, while rugby athletes were 1.57 times more likely to have the KCNH8 TT genotype, when compared to the control group. These results confirm the hypothesis that the aforementioned alleles and genotypes have an association with athletic performance and improvement of VO₂ max. Furthermore, the GRIN3A (rs1535628) variant did not associate with running performance, rugby playing position or rugby performance.

Insulin-like growth factor-1 (IGF-1) is associated with the development of muscle mass and strength [118]. It has been observed that the IGF-1 TT genotype (rs35767) presented a significantly higher frequency among Caucasian Israeli athletes at international level when compared to those at national level (p<0.02). This suggests that the TT genotype may have a possible contribution to endurance performance and, in particular, to excellence in strength-related sports [119]. Additionally, IGF 1245T (rs35767) polymorphism may contribute to long-distance running success, although not necessarily to elite performance [111]. On the other hand, Ben-Zaken et al. [120] found no significant association between the IGF-1R 275,124 A>C (rs1464430) and strength or endurance compared when compared to the control group.

Interleukin-6 (IL-6) is a multifunctional cytokine, which, in high circulating concentrations after exercise, is related to training duration and intensity, muscle mass recruitment and resistance capacity [16, 121, 122].

The analysis of the IL-6 polymorphism by Ben- Zaken et al. [121] demonstrated that the CC genotype and the frequency of the C allele were significantly higher in long-distance swimmers compared to long- and medium-distance runners. The authors also suggested that the use of genetic polymorphisms could be an additional tool for identifying and selecting talents in sports, as well as helping to build effective training programs. In another study conducted by Ben-Zaken et al. [123], it was observed that the prevalence of the IL-6 C and IGFBP3C mutations was significantly higher among long-distance swimmers (44%) compared to long-distance runners (21%).

It has been observed that NOS3 is related to the aerobic capacity of athletes [124], strength and endurance exercise performance [125]. Studies indicate that the NOS3 gene is considered a candidate for athlete status and physical performance. The NOS3 (rs1799983) polymorphism, in particular the G894 allele, may favor all types of sports, with a greater predisposition among power-oriented athletes [126]. Furthermore, another study suggested that the Glu allele of the NOS3 G894T polymorphic site (rs1799983) is disadvantageous in female short-distance swimmers, whereas the T allele of the 786T/C polymorphism (rs2070744) may be beneficial for long-distance swimmers [127].

Peroxisome proliferator-activated nuclear receptors (PPARs) have three different forms (PPAR α , PPAR β / δ , and PPAR γ), which are encoded by similar genes (PPARA, PPARD, and PPARG, respectively) [128]. Variants of the peroxisome proliferator activated receptor alpha (PPARA) (rs4253778) and peroxisome proliferator-activated receptor gamma coactivator-1 genes (PPARGC1A) Gly482Ser have been associated with endurance performance and aerobic capacity [129]. In soccer players, the frequency distributions for the PPARA alleles/genotypes (rs4253778) seem to favor resistance to fatigue [58]. In the cohort of endurance athletes, the odds ratio for those with the 'ideal genotype' (PPARD CC+PPARGC1A Gly/Gly+PPARGC1A Gly/Ser) to be elite-level athletes was 8.32 [130].

The PPARA polymorphism (rs4253778) was positively associated with endurance athlete status (GG genotype and G allele) in the elite group of Polish rowers [131]. In three cohorts of elite gymnasts (Polish, Italian and Lithuanian), the PPARA gene polymorphism (rs4253778) showed a higher frequency of the CC genotype when grouped and compared with a control group. However, when the cohorts were analyzed separately, no statistically significant differences were found in any of the analyses [132]. On the other hand, it is important to point out the limitations of the aforementioned study, including a small sample size of European artistic gymnasts, exclusively male and the limited number of polymorphisms analyzed.

Six groups of authors also focused on PPAR genes and their polymorphisms. Maciejewska-Karlowska et al. [133] pointed out that the rs2016529 and rs1053049 polymorphisms of the peroxisome proliferator-activated receptor delta gene (PPARD) were individually associated with elite athletic performance, whereas the PPARD A/C/C haplotype (rs2267668/rs2016520/rs1053049) were significantly underrepresented in athletes compared to controls, suggesting that A/C/C haplotypes may be unfavorable for achieving elite athletic performance. A low frequency of the 482Ser allele of the PPARGC1A gene was observed in Polish and Russian endurance athletes [134]. Ginevičienė et al. [135] suggested that PPARGC1A (rs8192678) and PPARA (rs4253778) polymorphisms, separately or combined with ACE (I/D), are associated with the performance of male soccer players. Having the AG genotype of NRF2, along with the Gly/Gly+Gly/Ser genotypes of PPARGC1A, could be the "ideal genotype" for endurance athletes [13]. On the other hand, Jin et al. [136] did not find associations between PPARD T294C rs2016520 and PPARGC1A Gly482Ser (rs8192678) polymorphisms and elite athletic status. Likewise, Ben-Zaken et al. [32] found no significant difference in the PPARD polymorphism (rs2016520) when comparing sprinters, jumpers and weight lifters with controls.

A study by Proia et al. [137] demonstrated an association between the PPARA polymorphism (rs4253778) and endurance performance. In that study, the G allele and the GG genotype were significantly more frequent in soccer players when compared to controls. However, Meckel et al. [69] found no significant difference in the PPARD 294CC polymorphism (rs2016520) when comparing soccer athletes with sprinters/jumpers and long-distance runners.

Studies with the polymorphism G protein subunit beta 3 (GNB3) C825T point out that there is a relationship between this polymorphism and the development of coronary artery disease [138], obesity [139] and heart rate and blood pressure response to resistance training [140]. Our results showed that Israeli athletes with the TT genotype of GNB3 have a 4.49 times higher chance of being endurance athletes [141]. However, its association with athletic status was not confirmed by Sawczuk et al. [142].

Guilherme et al. [73] evaluated 23 polymorphisms in 20 genes in a Brazilian cohort of 656 athletes and 966 non-athletes. They observed that only carriers of the A allele of the AGT M268T gene (rs699) were associated with endurance status. Another gene described in our review was the angiotensin II receptor type 2 (AGTR2), which is a component of the renin-angiotensin system (RAS), involved in the control of the circulatory system and blood pressure [143]. RAS acts on angiotensin II receptor, type 1 (AGTR1) and AGTR2. While AGTR2 can act as a vasodilator, antifibrotic, natriuretic and anti-inflammatory, AGTR1 has the opposite effects [73]. Mustafina et al. [144] analyzed 15 polymorphisms, including the AGTR2 C allele (rs11091046) and concluded that it may be associated with endurance athlete status, increased slow-twitch muscle fibers, and aerobic performance.

The literature indicates that the vascular endothelial growth factor receptor 2 (VEGFR2) His472Gln polymorphism is associated with elite athlete status, endurance performance in female rowers, and muscle fiber type composition [145]. Eider et al. [84] suggested this polymorphism as a genetic marker in endurance athletes, although more experimental studies involving elite athletes are needed. However, Ercan et al. [146] found no association between the VEGFR2 (rs2305948) polymorphism and performance in Turkish endurance athletes.

Other examples of polymorphisms related to the status of endurance athletes, which make up our results, are the NRF-2 A/C (rs12594956) and solute carrier family 2 member 4 (SLC2A4) (rs5418) polymorphisms. Eynon et al. [66] noted that endurance athletes showed a higher frequency of the AA genotypes of NRF-2 (rs12594956) and CT genotypes of NRF-2 (rs8031031) compared to sprinters and control groups. In a subsequent study, Eynon et al. [99] found that the frequency of the AA genotype of the NRF-2 A/C polymorphism (rs12594956) was significantly higher in endurance athletes compared to strength athletes and controls. Concomitantly, the A allele of the SLC2A4 polymorphism (rs5418) was overrepresented in Chinese athletes when compared to controls [147].

Genetic polymorphisms and strength, power and speed performance

The ability of skeletal muscle to produce force is strongly influenced by genetics [148, 149]. Studies have investigated genetic markers related to strength status, such as the A allele of the leucine-rich pentatricopeptide repeat cassette (LRPPRC) (rs10186876), T allele of the methyl methanesulfonate-sensitivity protein 22-like (MMS22L) (rs9320823), C allele of the methylenetetrahydrofolate reductase (MTHFR) (rs1801131) [150], C allele of the phosphate and actin regulator 1 (PHACTR1) (rs6905419) in Russian weightlifters [16], T allele of the ciliary neurotrophic factor (CNTF) (rs41274853) in Japanese weightlifters [148], G allele of the carnosine Dipeptidase 2 (CNDP2) (rs3764509), C allele of the CNDP2-CNDP1 (rs2346061), A allele of the CNDP1 (rs2887) in Brazilian athletes [151], 12Ala allele of the PPARG (rs1801282) in Polish athletes [152], T allele of the GALNTL6 (rs558129) in Spanish and Russian athletes [153], and the C allele of the M235T polymorphism of AGT in Polish athletes [154]. In addition of these, the hypoxia inducible factor 1 subunit alpha (HIF1A) (rs11549465) [155] and AGTR2 (rs11091046) [156] polymorphisms have been linked to strength.

The fat mass and obesity associated polymorphism (FTO) (rs9939609) is widely recognized for its association with higher body mass indexes (BMI) and body fat content [157]. In a study carried out with elite athletes from two cohorts (Brazil and Russia), it was observed that the polymorphism FTO T>A (rs9939609) was overrepresented in heavier athletes [158]. Therefore, individuals carrying the TT genotype of the FTO polymorphism (rs9939609) may have advantage in succeeding in sports such as swimming. As a matter of fact, anthropometry and body composition, influenced by the FTO A/T polymorphism, play a crucial role in sports performance [159]. Furthermore, another study, carried out in the Russian population, showed a significant effect of the interaction between the FTO rs9939609 and physical activity, specifically aerobic sports activities, on BMI of young amateur and professional athletes [160]. However, in a study that compared European athletes from Spain, Poland and Russia, no association was found between FTO allele and genotype frequencies and elite athletic status [161].

According to Wojciechowicz et al. [162], the apolipoprotein E polymorphism (APOE) TC (rs429358) was overrepresented in power athletes. Furthermore, polymorphisms of the KIF6 (rs20455) and APOE (rs7412) genes were associated with power performance, but not with endurance performance, suggesting a possible relationship between KIF6 and APOE, or interactions at the molecular level, in modulating strength performance.

When analyzing the solute carrier family 6 member 2 polymorphism (SLC6A2) (rs1805065), Guilherme et al. [163] verified that the presence of the T allele may decrease the chance of the athlete being involved in explosive physical tasks. although there seems to be an association of this polymorphism with power status. For Ginevičienė et al. [164], the genotype and/or allele frequencies of the c.*800A>G (rs8111989) in the muscle-specific creatine kinase (CKM) gene do not seem to influence the performance of weightlifters and powerlifters from Russia and Lithuania. The SNPs of CKM (rs344816, rs10410448, rs432979, rs1133190, rs7260359, rs7260463, rs4884) were not associated with the endurance performance of elite athletes [110]. Additionally, similar results were found in athletes whose anaerobic energy pathways are used to determine the success of elite athletes. Furthermore, the results indicate that G allele carriers of the CKM gene (rs8111989) are not predisposed to excel in power and strength sports.

A previous study demonstrated that the IGF-1 TT genotype (rs35767) is associated with endurance performance in Israeli track and field athletes [119]. However, regarding decathletes, Ben-Zaken et al. [165] suggested that the IGF1 TT (rs35767) and IGF-2 GG (rs680) genotypes are associated with better speed performance. These findings indicate that the IGF-1 TT genotype may influence athletic performance in different aspects such as endurance and speed. When analyzing the polymorphism (rs1464430) of the insulin-like growth factor receptor (IGF-1R) in Israeli elite athletes, Ben-Zaken et al. [120] suggested that the IGF-1R genotype may be beneficial for endurance-related sport, but not for elite endurance performance.

In a study that evaluated the frequency of the IGF2 polymorphism (rs680) in Israeli athletes and controls, the authors found a significant difference in the frequency of the GG genotype among runners when compared to weightlifters, suggesting a beneficial association of this polymorphism with speed rather than strength-related sports. However, no significant differences were found in relation to carriers of the GG genotype when comparing distance runners, swimmers (short and long distance), weightlifters and controls [166]. On the other hand, the G allele of this polymorphism may be associated with strength status in judo athletes [79].

Catechol-O-methyltransferase (COMT) is a gene involved in the metabolism of catecholamines, including dopamine, epinephrine, and norepinephrine [167]. A study carried out with mixed martial arts fighters suggested that these individuals have significantly higher frequency of the GG genotype of the COMT polymorphism (rs4680) than non-athletes [168]. However, Zmijewski et al. [169] showed no association between COMT with elite swimming status. The lack of association to establish the role of COMT polymorphism in athletes can be explained by the limitations of the previously mentioned study and solved with future replication studies.

The rs1799725 polymorphism, related to a variation in the SOD2 gene, is responsible for encoding the enzyme superoxide dismutase 2 (MnSOD). This polymorphism has been reported to be represented by the C (which codes for the amino acid alanine (Ala)) and the T allele (which codes for the amino acid valine (Val)) [170]. In a meta-analysis study, the MnSOD polymorphism (rs1799725) was identified as an influential factor in power phenotype [171]. Ben-Zaken et al. [172] evaluated Israeli endurance and power athletes and found that carriers of the MnSOD Ala/Ala genotype (rs1799725) had significantly higher results (p < 0.05) among elite athletes at international and Olympic levels compared to national level athletes. The Ala allele, on the other hand, presented a significantly higher frequency among endurance and power athletes compared to controls (p < 0.001). Interestingly, endurance and power athletes showed similar allelic distribution, suggesting that the beneficial effect of MnSOD is not mediated through aerobic pathways. Instead, it may be related to reactive oxygen species, mitochondrial biosynthesis and muscle hypertrophy.

Genetic markers linked to antioxidant action have shown association with power athletes [170]. The ALDH2 rs671 polymorphism has been studied in relation to human diseases, particularly associated with cardiometabolic risk factors [173]. Regarding physical performance, it has been associated with athletic status and muscular strength in a Japanese population [174]. However, our results did not confirm the relationship between the ALDH2 rs671 polymorphism and athletic status in power/strength athletes [175].

Other studies associate genetic polymorphisms with power athletic status, such as: MCT1 D490E (T allele), AGT M268T (G allele), PPARG (C allele), PGC1A G482S (C allele), VEGFR2 Q472H (T allele), NOS3 C/T (T allele) and ACTN3 R577X (R allele) in Brazilian athletes [73], AGT M235T (CC genotype) in Spanish athletes [176], NOS3 rs2070744 (TT genotype and T allele) in Spanish athletes [125], and PPARGC1A (Ser/Ser genotype) in weightlifters from two European cohorts [78] and MCT1 T1470A (AA genotype) in Japanese athletes [177].

Rs1867785/rs11689011 polymorphisms of the endothelial PAS domain protein 1 (EPAS1) were found to be strong predictors of sprint/power athletic status. Additionally, the interaction between the rs1867785, rs11689011, and rs4035887 polymorphisms may contribute to success in sprint/power athletic performance [178]. Other polymorphisms associated with elite status in sprint/ power sports were mentioned in our review, including AMPD1 (C allele) [179], the ADRB2 alleles (Gly16 and Gly27 allele) [180], MCT1 A147T (TT genotype) [181], the genotype TT from CNTFR (rs41274853) [182] and the A allele from ACVR1B (rs2854464) [183], higher frequency of the C allele of AMPD1 [179] and lower frequency of the T allele of AMPD1 (C34T) [184].

The findings presented in this review provide evidence to support the hypothesis that athletic performance may be influenced by genetic factors in different sports. However, it should be noted that most studies state that their studies are limited by the sample size, quality of genotype/phenotype measurement and the number of polymorphisms analyzed.

The limitations of the study should be considered in the interpretation of the results, since the case-control studies included in the review present considerable variability in their findings. This heterogeneity complicates drawing definitive conclusions about the specific influence of genetic polymorphisms on performance parameters such as muscle strength, endurance, speed, and respiratory capacity. Differences in study design, participant characteristics, and measurement methods contribute to this variability. Additionally, many of the analyzed studies have small sample sizes, which limits statistical power and generalizability, increasing the risk of Type II errors and potentially leading to overestimation or underestimation of genetic effects on athletic performance. There is also inconsistency in how performance parameters were measured and reported across studies, with frequently divergent definitions and evaluations for endurance, strength, speed, and power, which complicates direct comparisons and may obscure true associations between genetic polymorphisms and performance outcomes. Variability in sports modalities may also influence how genetic polymorphisms affect performance. The inclusion of a broad range of sports, from endurancebased to strength-based disciplines, complicates the generalization of findings. Lastly, most of the included studies were cross-sectional, assessing genetic polymorphisms and performance at a single point in time; longitudinal studies are needed to better understand how genetic factors influence the development and progression of performance throughout an athlete's career.

Future perspectives

Genetic factors have been proposed as potential determinants of sports talents or the traits associated with them. In our review, we examined studies that linked genetic polymorphisms with resistance, strength, power, and speed performance. These studies provided valuable insights that may assist athletes and coaches in understanding the factors that contribute to athletic performance, as some findings displayed promising data. A large number of articles describe athletic status but actually specify improvements in activities performed in sports. However, it is important to acknowledge that our study evaluated only a subset of the numerous polymorphisms associated with performance, and other factors such as environmental influences and unexplored genetic variants could have influenced the results. Therefore, our current understanding of this subject is limited, and further research is necessary to establish the utility of genetic polymorphisms in the identification of sports talents. Future studies should aim to establish more precise associations between genetic profiles and sports talents. This research can significantly facilitate the talent identification and development process by providing a more comprehensive understanding of the genetic factors influencing athletic performance.

Conclusion

This study aimed to investigate the influence of genetic polymorphisms on the performance of sports talents compared to non-athletes. Our results indicated that the ACE I/D and ACTN3 R577X polymorphisms are the most extensively studied in the literature. We found that the ACTN3 XX genotype is frequently associated with an endurance phenotype, while the RR genotype tends

Medline to be more common among speed, power, and strength MeSH athletes. Regarding the ACE polymorphism, the I allele MMS22I MnSOD is associated with endurance sports, while the D allele is more related to power-oriented sports. Different genetic polymorphisms play crucial roles in influencing athletic performance across various disciplines, and conduct ing studies to identify and select sports talents is recom mended to confirm associations in diverse population and sports. However, we observed heterogeneity in th results of the analyzed studies, making it challenging to evaluate specific factors related to physical performance Furthermore, many studies that associate polymorphism with athletic status presented inconsistent data when considering performance parameters such as endurance strength, speed, and power. These inconsistencies ma be attributed to the unique characteristics of each sport discipline, as well as the use of small sample sizes. Mor research is needed to provide a more precise confirma tion of the influence of genetic polymorphisms on elit

Abbreviations

athletes in various contexts and sports.

	A
ACE	Angiotensin converting enzyme
ACTN3	α-actinin-3
ACVR1B	Activin A receptor type 1B
ADRB2	β-adrenergic receptors
AGT	Angiotensinogen
AGTR1	Angiotensin II receptor, type 1
AGTR2	Angiotensin II receptor, type 2
AMPD1	Adenosine monophosphate deaminase 1
APOE	Apolipoprotein E
BDKRB2	Bradykinin receptor B2
BMI	Body mass index
BVS	Virtual health library
CHRNB3	Cholinergic receptor nicotinic beta 3 subunit
CKM	Muscle-specific creatine kinase
CNDP1	Carnosine dipeptidase 1
CNDP2	Carnosine dipeptidase 2
CNTF	Ciliary neurotrophic factor
CNTFR	Ciliary neurotrophic factor receptor
COMT	Catechol-O-methyltransferase
CUMED	National Information Center for Medical Sciences of
	Cuba
DeCS	Health sciences descriptors
EPSA1	Endothelial PAS domain protein 1
FTO	Fat mass and obesity associated
GALNTL6	N-acetylgalactosaminyltransferase-like 6 gene
GNB3	G protein subunit beta 3
GRIN3A	Glutamate ionotropic receptor NMDA type subunit 3 A
HIF1A	Hypoxia inducible factor 1 subunit alpha
IBECS	Spanish Bibliographic Index in Health Sciences
IGF-1R	Insulin-like growth factor 1 receptor
IGFBP3	Insulin like growth factor binding protein 3
IGFBP3C	Mutation of insulin like growth factor binding protein 3
IGF-1	Insulin-like growth factor 1
IGF-2	Insulin-like growth factor 2
IL-6	Interleukin-6
IL-6C	Mutation of interleukin-6
KCNH8	Potassium voltage-gated channel subfamily H member
ICINI IO	8
KIF6	o Kinesin family member 6
LILACS	Latin American and Caribbean Literature in Health
LILMCO	
	Sciences
LRPPRC	Leucine-rich pentatricopeptide repeat cassette
MCT1	Monocarboxylate transporter 1

	MSTN	Myostatin
ic	MTHFR	Methylenetetrahydrofolate reductase
ic	NOS3	Nitric oxide synthase 3
:t-	NRF-2	Nuclear respiratory factor 2
	OR	Odds ratio
n-	PGC1A	Peroxisome proliferator-activated receptor y coactivator
ns		1-alpha
ne	PHACTR1	Phosphate and actin regulator 1
	PPAR $_{f y}$ or PPARG	Peroxisome proliferator-activated receptor gamma
to	PPARGC1A	Peroxisome proliferator-activated receptor gamma
æ.		coactivator-1 alpha
ns	PPARs	Peroxisome proliferator-activated nuclear receptors
en	PPARa or PPARA	Peroxisome proliferator activated receptor alpha
	PPARβ/δ or PPARD	Peroxisome proliferator-activated receptor delta
æ,	PRDM1	PR/SET Domain 1
ay	PRISMA	Preferred Reporting Items for Systematic Reviews and
ts		Meta-Analysis statement
	SCIELO	Scientific Electronic Library Online
re	SLC2A4	Solute carrier family 2 member 4
a-	SLC6A2	Solute carrier family 6 member 2
te	STREGA	Strengthening the Reporting of the Genetic Association
	STROBE	Reporting of observational studies in epidemiology
	VEGFR2	Vascular endothelial growth factor receptor 2
	VO ₂ max WPRIM	Maximal oxygen consumption
		Western Pacific Region Index Medicus

Medical subject headings

Superoxide dismutase 2

Supplementary Information

The online version contains supplementary material available at https://doi.or g/10.1186/s13102-024-01001-5.

Supplementary Material 1 (S1): Includes a comprehensive overview of the study's key components: Table 1 categorizes the selected articles according to polymorphism type, sample size, main findings, authorship, and year of publication; Table 2 details the characteristics of the participants analyzed; and Table 3 provides a quality assessment of the studies based on the Strengthening the Reporting of Genetic Association Studies (STREGA) Statement

Supplementary Material 2 (S2): Outlines the search strategy, lists articles included and excluded from the study, presents the STREGA checklist, and identifies the articles incorporated into the meta-analysis focusing on ACTN3 and ACE polymorphisms

Supplementary Material 3 (S3): Encompasses the Modified STROBE quality score systems applied in the study

Acknowledgements

We would like to thank Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Foundation for Research and Scientific and Technological Development of Maranhão (FAPEMA BD-02488/21), and Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP#2018/16565-0) for supporting this study.

Author contributions

Conceptualization, CPF, VOS, and MAPS; methodology, preparation of Figs. 1, 2, 3, 4 and 5, VOS and CPF; formal analysis, CPF, RGT, and RCM; investigation, CPF, SSA, and MAPS; writing – original draft preparation, CPF; writing – review and editing, CPF, VOS, and RGT; supervision, MAPS and SSA; project administration, MAPS. All authors have read and agreed to the published version of the manuscript.

Funding

This study received no external funding.

Medical Literature Analysis and Retrievel System Online

Methyl methanesulfonate-sensitivity protein 22-like

Data availability

The datasets analyzed in this manuscript are not publicly available but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 16 August 2023 / Accepted: 27 September 2024 Published online: 31 October 2024

References

- Fonseca EJ, Melo HCS. The use of VO2 max in the detection of talents in sports performance in elementary school student's process. Rev Acta Científica. 2017;8. https://doi.org/10.21745/ac08-09
- Fernandes RA, López-Plaza D, Correas-Gómez L, et al. The importance of biological maturation and years of practice in kayaking performance. Int J Environ Res Public Health. 2021;18. https://doi.org/10.3390/ijerph18168322
- Peplonska B, Adamczyk JG, Siewierski M, et al. Genetic variants associated with physical and mental characteristics of the elite athletes in the Polish population. Scand J Med Sci Sport. 2017;27:788–800. https://doi.org/10.1111/ sms.12687
- Yang J, Benyamin B, McEvoy BP, et al. Common SNPs explain a large proportion of the heritability for human height. Nat Genet. 2010;42:565–9. https://d oi.org/10.1038/ng.608
- Pickering C, Kiely J, Grgic J, et al. Can genetic testing identify talent for sport? Genes (Basel). 2019;10. https://doi.org/10.3390/genes10120972
- Moran CN, Pitsiladis YP. Tour De France champions born or made: where do we take the genetics of performance? J Sports Sci. 2017;35:1411–9. https://d oi.org/10.1080/02640414.2016.1215494
- Ahmetov II, Hall ECR, Semenova EA, et al. Advances in sports genomics. Adv Clin Chem. 2022;107:215–63. https://doi.org/10.1016/bs.acc.2021.07.004
- de Albuquerque-Neto SL, Herrera JJB, Rosa TS, et al. Interaction between ACTN3 (R577X), ACE (I/D), and BDKRB2 (-9/+9) polymorphisms and endurance phenotypes in Brazilian long-distance swimmers. J Strength Cond Res. 2020;1:1–5. https://doi.org/10.1519/JSC.00000000003685
- Peña-Vázquez O, Enriquez-del Castillo LA, González-Chávez SA, et al. Prevalence of polymorphism and post-training expression of ACTN3 (R/X) and ACE (I/D) genes in CrossFit Athletes. Int J Environ Res Public Health. 2023;20. https://doi.org/10.3390/ijerph20054404
- 10. Vostrikova A, Pechenkina V, Danilova M, et al. Gene polymorphism and Total Genetic Score in Martial Arts Athletes with different athletic qualifications. Genes (Basel). 2022;13. https://doi.org/10.3390/genes13091677
- 11. Zarębska A, Jastrzębski Z, Moska W, et al. The agt gene m235t polymorphism and response of power-related variables to aerobic training. J Sport Sci Med. 2016;15:616–24.
- Maciejewska-Skrendo A, Cięszczyk P, Chycki J, et al. Genetic markers associated with power athlete status. J Hum Kinet. 2019;68:17–36. https://doi.org/1 0.2478/hukin-2019-0053
- Eynon N, Sagiv MM, Meckel Y, et al. NRF2 intron 3 A/G polymorphism is associated with endurance athletes' status. J Appl Physiol. 2009;107:76–9. htt ps://doi.org/10.1152/japplphysiol.00310.2009
- Eynon N, Alves AJ, Sagiv M, et al. Interaction between SNPs in the NRF2 gene and elite endurance performance. Physiol Genomics. 2010;41:78–81. https:// doi.org/10.1152/physiolgenomics.00199.2009
- Gronek P, Gronek J, Lulińska-Kuklik E, et al. Polygenic study of endurance-Associated genetic markers NOS3 (Glu298Asp), BDKRB2 (-9/+9), UCP2 (Ala55Val), AMPD1 (Gln45Ter) and ACE (I/D) in Polish Male Half marathoners. J Hum Kinet. 2018;64:87–98. https://doi.org/10.1515/hukin-2017-0204
- 16. Kikuchi N, Moreland E, Homma H, et al. Genes and weightlifting performance. Genes (Basel). 2022;13. https://doi.org/10.3390/genes13010025

- Chung HC, Keiller DR, Roberts JD, Gordon DA. Do exercise-associated genes explain phenotypic variance in the three components of fitness? A systematic review & meta-analysis. PLoS ONE. 2021;16. https://doi.org/10.1371/journ al.pone.0249501
- Ginevičienė V, Jakaitienė A, Pranckevičienė E, et al. Variants in the myostatin gene and physical performance phenotype of elite athletes. Genes (Basel). 2021;12. https://doi.org/10.3390/genes12050757
- Webborn N, Williams A, McNamee M, et al. Direct-to-consumer genetic testing for predicting sports performance and talent identification: Consensus statement. Br J Sports Med. 2015;49:1486–91. https://doi.org/10.1136/bjsport s-2015-095343
- Varillas-Delgado D, Morencos E, Gutiérrez-Hellín J, et al. Genetic profiles to identify talents in elite endurance athletes and professional football players. PLoS ONE. 2022;17:e0274880. https://doi.org/10.1371/journal.pone.0274880
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10. https:/ /doi.org/10.1186/s13643-021-01626-4
- 22. Galvão TF, Pereira MG. Revisões sistemáticas da literatura: passos para sua elaboração. Epidemiol E Serviços Saúde. 2014;23:183–4.
- 23. Little J, Higgins JPT, Ioannidis JPA, et al. STrengthening the REporting of genetic association studies (STREGA)-an extension of the strobe statement. PLoS Med. 2009;6:0151–63. https://doi.org/10.1371/journal.pmed.1000022
- Liu Y, Li L, Qi H, et al. Survivin 31G>C polymorphism and gastrointestinal Tract Cancer risk: a Meta-analysis. PLoS ONE. 2013;8. https://doi.org/10.1371/j ournal.pone.0054081
- Serdar CC, Cihan M, Yücel D, Serdar MA. Sample size, power and effect size revisited: simplified and practical approachin pre-clinical, clinical and laboratory studies. Biochem Med. 2021;31:1–27. https://doi.org/10.11613/BM.2021. 010502
- Andrade C. Learning curve: sample size and its importance in Research. Indian J Psychol Med. 2020;42:138–43. https://doi.org/10.4103/JJPSYM.JJPSYM
- Varillas-Delgado D, Del Coso J, Gutiérrez-Hellín J, et al. Genetics and sports performance: the present and future in the identification of talent for sports based on DNA testing. Eur J Appl Physiol. 2022;122:1811–30. https://doi.org/1 0.1007/s00421-022-04945-z
- Naureen Z, Perrone M, Paolacci S, et al. Genetic test for the personalization of sport training. Acta Biomed. 2020;91:1–15. https://doi.org/10.23750/abm.v91i 13-S.10593
- 29. De Moor MHM, Spector TD, Cherkas LF, et al. Genome-wide linkage scan for athlete status in 700 British female DZ twin pairs. Twin Res Hum Genet. 2007;10:812–20. https://doi.org/10.1375/twin.10.6.812
- Peeters MW, Thomis MA, Loos RJF, et al. Heritability of somatotype components: a multivariate analysis. Int J Obes. 2007;31:1295–301. https://doi.org/10 .1038/sj.ijo.0803575
- Ginszt M, Michalak-Wojnowska M, Gawda P, et al. Actn3 genotype in Professional Sport climbers. J Strength Cond Res. 2018;32:1311–5.
- Ben-Zaken S, Eliakim A, Nemet D, Meckel Y. Genetic variability among power athletes: the stronger vs: the faster. J Strength Cond Res. 2019;33:1505–11. https://doi.org/10.1519/JSC.00000000001356
- Grover VK, Verma JP, Kumar A, et al. A statistical model for ACTN3 genotype in elite power and speed athletes. J Stat Manag Syst. 2020;23:239–48. https://do i.org/10.1080/09720510.2020.1724624
- 34. Min SK, Jee E, Lee K, et al. The ACTN3 R577Xgth in Korea national combat athletes. Sci Sport. 2021;36. https://doi.org/10.1016/j.scispo.2021.01.003. :236. e1-236.e6.
- Ahmetov II, Egorova ES, Gabdrakhmanova LJ, Fedotovskaya ON. Genes and athletic performance: an update. Genet Sport. 2016;61:41–54. https://doi.org/ 10.1159/000445240
- Tharabenjasin P, Pabalan N, Jarjanazi H. Association of the ACTN3 R577X (rs1815739) polymorphism with elite power sports: a meta-analysis. PLoS ONE. 2019;14:1–20. https://doi.org/10.1371/journal.pone.0217390
- 37. Wei Q. The ACE and ACTN3 polymorphisms in female soccer athletes. Genes Environ. 2021;43:4–11. https://doi.org/10.1186/s41021-021-00177-3
- Kim H, Song K-H, Kim C-H. The ACTN3 R577X variant in sprint and strength performance. J Exerc Nutr Biochem. 2014;18:347–53. https://doi.org/10.5717/ jenb.2014.18.4.347
- Yang N, MacArthur DG, Gulbin JP, et al. ACTN3 genotype is associated with human elite athletic performance. Am J Hum Genet. 2003;73:627–31. https:// doi.org/10.1086/377590
- 40. Silva HH, Silva MRG, Cerqueira F, et al. Genomic profile in association with sport-type, sex, ethnicity, psychological traits and sport injuries of elite

athletes. J Sports Med Phys Fit. 2022;62:418–34. https://doi.org/10.23736/S00 22-4707.21.12020-1

- Baltazar-Martins G, Gutiérrez-Hellín J, Aguilar-Navarro M, et al. Effect of ACTN3 genotype on sports Performance, Exercise-Induced muscle damage, and Injury Epidemiology. Sports. 2020;8:1–12. https://doi.org/10.3390/sports8070 099
- 42. Ma F, Yang Y, Li X, et al. The Association of Sport Performance with ACE and ACTN3 genetic polymorphisms: a systematic review and Meta-analysis. PLoS ONE. 2013;8:1–9. https://doi.org/10.1371/journal.pone.0054685
- Gunel T, Gumusoglu E, Hosseini MK, et al. Effect of angiotensin I-converting enzyme and α-actinin-3 gene polymorphisms on sport performance. Mol Med Rep. 2014;9:1422–6. https://doi.org/10.3892/mmr.2014.1974
- Ruiz JR, Santiago C, Yvert T, et al. ACTN3 genotype in Spanish elite swimmers: no heterozygous advantage. Scand J Med Sci Sport. 2013;23:1–6. https://doi. org/10.1111/sms.12045
- Orysiak J, Sitkowski D, Zmijewski P, et al. Overrepresentation of the ACTN3 XX genotype in Elite Canoe and Kayak paddlers. J Strength Cond Res. 2015;29:1107–12. https://doi.org/10.1519/JSC.000000000000717
- de Albuquerque-Neto SL, dos Santos MAP, Silvino VO, et al. Association between ACTN3 (R577X), ACE (I/D), BDKRB2 (-9/+9), and AGT (M268T) polymorphisms and performance phenotypes in Brazilian swimmers. BMC Sports Sci Med Rehabil. 2024;16:1–10. https://doi.org/10.1186/s13102-024-00828-2
- Ben-Zaken S, Eliakim A, Nemet D, et al. ACTN3 polymorphism: comparison between Elite swimmers and runners. Sport Med - Open. 2015. https://doi.or g/10.1186/s40798-015-0023-y. 1:.
- Eynon N, Duarte JA, Oliveira J, et al. ACTN3 R577X polymorphism and Israeli top-level athletes. Int J Sports Med. 2009;30:695–8. https://doi.org/10.1055/ s-0029-1220731
- Eynon N, Ruiz JR, Femia P, et al. The ACTN3 R577X polymorphism across three groups of elite male European athletes. PLoS ONE. 2012;7. https://doi.org/10. 1371/journal.pone.0043132
- Lucia A, Gómez-Gallego F, Santiago C, et al. ACTN3 genotype in professional endurance cyclists. Int J Sports Med. 2006;27:880–4. https://doi.org/10.1055/ s-2006-923862
- Yamak B, Yuce M, Bagci H, Imamoglu O. Association between sport performance and alpha-actinin-3 gene R577X polymorphism. Int J Hum Genet. 2015;15:13–9. https://doi.org/10.1080/09723757.2015.11886246
- Döring FE, Onur S, Geisen U, et al. Actn3 r577x and other polymorphisms are not associated with elite endurance athlete status in the genathlete study. J Sports Sci. 2010;28:1355–9. https://doi.org/10.1080/02640414.2010.507675
- Druzhevskaya AM, Ahmetov II, Astratenkova IV, Rogozkin VA. Association of the ACTN3 R577X polymorphism with power athlete status in russians. Eur J Appl Physiol. 2008;103:631–4. https://doi.org/10.1007/s00421-008-0763-1
- Ahmetov II, Druzhevskaya AM, Astratenkova IV, et al. The ACTN3 R577X polymorphism in Russian endurance athletes. Br J Sports Med. 2010;44:649–52. https://doi.org/10.1136/bjsm.2008.051540
- Yang R, Shen X, Wang Y, et al. Actn3 R577X gene variant is associated with muscle-related phenotypes in elite Chinese sprint/power athletes. J Strength Cond. 2017;31:1107–15. https://doi.org/10.1519/JSC.000000000001558
- Hong SS, Jin HJ. Assessment of association of ACTN3 genetic polymorphism with Korean elite athletic performance. Genes Genomics. 2013;35:617–21. https://doi.org/10.1007/s13258-013-0111-7
- Shang X, Huang C, Chang Q, et al. Association between the ACTN3 R577X polymorphism and female endurance athletes in China. Int J Sports Med. 2010;31:913–6. https://doi.org/10.1055/s-0030-1265176
- Murtagh CF, Brownlee TE, Rienzi E, et al. The genetic profile of elite youth soccer players and its association with power and speed depends on maturity status. PLoS ONE. 2020;15:1–24. https://doi.org/10.1371/journal.pone.023445 8
- Ginevičiene V, Pranculis V, Jakaitiene V, et al. Genetic variation of the human ACE and ACTN3 genes and their association with functional muscle properties in Lithuanian elite athletes. Med. 2011;47:284–90. https://doi.org/10.3390 /medicina47050040
- Djarova T, Bardarev D, Boyanov D, et al. Performance enhancing genetic variants, oxygen uptake, heart rate, blood pressure and body mass index of elite high altitude mountaineers. Acta Physiol Hung. 2013;100:289–301. https://do i.org/10.1556/APhysiol.100.2013.3.5
- Eynon N, Banting LK, Ruiz JR, et al. ACTN3 R577X polymorphism and teamsport performance: a study involving three European cohorts. J Sci Med Sport. 2014;17:102–6. https://doi.org/10.1016/j.jsams.2013.02.005

- 62. Papadimitriou ID, Papadopoulos C, Kouvatsi A, Triantaphyllidis C. The ACTN3 gene in elite Greek track and field athletes. Int J Sports Med. 2008;29:352–5. https://doi.org/10.1055/s-2007-965339
- Orysiak J, Busko K, Michalski R, et al. Relationship between ACTN3 R577x polymorphism and maximal power output in elite Polish athletes. Med (B Aires). 2014;50:303–8. https://doi.org/10.1016/j.medici.2014.10.002
- Li Y, Wang LQ, Yi L, et al. ACTN3 R577X genotype and performance of elite middle-long distance swimmers in China. Biol Sport. 2017;34:39–43. https://d oi.org/10.5114/biolsport.2017.63731
- Dogan M, Aslan BT, Ulucan K. Comparison of potential biomarker, ACTN3 rs1815739 polymorphism, for athletic performance of Turkish athletes. Cell Mol Biol. 2022;68:54–9. https://doi.org/10.14715/cmb/2022.68.5.7
- 66. Eynon N, Alves AJ, Meckel Y, et al. Is the interaction between HIF1A P582S and ACTN3 R577X determinant for power/sprint performance? Metabolism. 2010;59:861–5. https://doi.org/10.1016/j.metabol.2009.10.003
- Ruiz JR, Fernández del Valle M, Verde Z, et al. ACTN3 R577X polymorphism does not influence explosive leg muscle power in elite volleyball players. Scand J Med Sci Sport. 2011;21. https://doi.org/10.1111/j.1600-0838.2010.011 34.x
- Moreno-Pérez V, Machar R, Sanz-Rivas D, Del Coso J. ACTN3 R577X genotype in professional and amateur tennis players. J Strength Cond Res. 2020;34:952–6. https://doi.org/10.1519/JSC.000000000003501
- Meckel Y, Eliakim A, Nemet D, et al. PPARD CC and ACTN3 RR genotype prevalence among elite soccer players. Sci Med Footb. 2020;4:156–61. https://doi.o rg/10.1080/24733938.2019.1677936
- Chiu LLL, Wu YF, Tang MT, et al. ACTN3 genotype and swimming performance in Taiwan. Int J Sports Med. 2011;32:476–80. https://doi.org/10.1055/ s-0030-1263115
- Yang S, Lin W, Jia M, Chen H. Association between ACE and ACTN3 genes polymorphisms and athletic performance in elite and sub-elite Chinese youth male football players. PeerJ. 2023;11. https://doi.org/10.7717/peerj.148 93
- 72. Akazawa N, Ohiwa N, Shimizu K, et al. The association of ACTN3 R577X polymorphism with sports specificity in Japanese elite athletes. Biol Sport. 2022;39:905–11. https://doi.org/10.5114/biolsport.2022.108704
- 73. Guilherme JPLF, Bertuzzi R, Lima-Silva AE, et al. Analysis of sports-relevant polymorphisms in a large Brazilian cohort of top-level athletes. Ann Hum Genet. 2018;82:254–64. https://doi.org/10.1111/ahg.12248
- 74. Mikami E, Fuku N, Murakami H, et al. ACTN3 R577X genotype is associated with sprinting in elite Japanese athletes. Int J Sports Med. 2014;35:172–7. https://doi.org/10.1055/s-0033-1347171
- Kikuchi N, Miyamoto-Mikami E, Murakami H, et al. ACTN3 R577X genotype and athletic performance in a large cohort of Japanese athletes. Eur J Sport Sci. 2016;16:694–701. https://doi.org/10.1080/17461391.2015.1071879
- Kikuchi N, Ueda D, Min SK, et al. The ACTN3 XX genotype's underrepresentation in Japanese elite wrestlers. Int J Sports Physiol Perform. 2013;8:57–61. https://doi.org/10.1123/ijspp.8.1.57
- Garatachea N, Verde Z, Santos-Lozano A, et al. ACTN3 R577X polymorphism and explosive leg-muscle power in elite basketball players. Int J Sports Physiol Perform. 2014;9:226–32. https://doi.org/10.1123/JJSPP.2012-0331
- Ginevičienė V, Jakaitiene A, Aksenov MO, et al. Association analysis of ACE, ACTN3 and PPARGC1A gene polymorphisms in two cohorts of European strength and power athletes. Biol Sport. 2016;33:199–206. https://doi.org/10. 5604/20831862.1201051
- Itaka T, Agemizu K, Aruga S, Machida S. G allele of the IGF2 Apal polymorphism is associated with judo status. J Strength Cond Res. 2016;30:2043–8. https://doi.org/10.1519/JSC.00000000001300
- Rodríguez-Romo G, Yvert T, De Diego A, et al. No association between ACTN3 R577X polymorphism and elite judo athletic status. Int J Sports Physiol Perform. 2013;8:579–81. https://doi.org/10.1123/ijspp.8.5:579
- Massidda M, Bachis V, Corrias L, et al. ACTN3 R577X polymorphism is not associated with team sport athletic status in italians. Sport Med - Open. 2015;1:3–7. https://doi.org/10.1186/s40798-015-0008-x
- Hwang IW, Kim K, Kwon BN, et al. Association of glutathione S-transferase M1 and T1 null/present polymorphism with physical performance in the Korean population. Genes Genomics. 2019;41:71–8. https://doi.org/10.1007/s1325 8-018-0737-6
- Miyamoto-Mikami E, Murakami H, Tsuchie H, et al. Lack of association between genotype score and sprint/power performance in the Japanese population. J Sci Med Sport. 2017;20:98–103. https://doi.org/10.1016/j.jsams. 2016.06.005

- Eider J, Cieszczyk P, Ficek K, et al. The association between D allele of the ACE gene and power performance in Polish elite athletes. Sci Sports. 2013;28:325– 30. https://doi.org/10.1016/j.scispo.2012.11.005
- Shahmoradi S, Ahmadalipour A, Salehi M. Evaluation of ACE gene I/D polymorphism in Iranian elite athletes. Adv Biomed Res. 2014;3:207. https://doi.or g/10.4103/2277-9175.143242
- Ahmetov II, Fedotovskaya ON. Current progress in Sports Genomics. Adv Clin Chem. 2015;70:247–314. https://doi.org/10.1016/bs.acc.2015.03.003
- Varillas-Delgado D, Tellería Orriols JJ, Del Coso J. Genetic profile in genes associated with cardiorespiratory fitness in elite Spanish male endurance athletes. Genes (Basel). 2021;12. https://doi.org/10.3390/genes12081230
- Falahati A, Arazi H. Association of ACE gene polymorphism with cardiovascular determinants of trained and untrained Iranian men. Genes Environ. 2019;41:1–8. https://doi.org/10.1186/s41021-019-0126-7
- Ash GI, Scott RA, Deason M, et al. No association between ACE gene variation and endurance athlete status in ethiopians. Med Sci Sports Exerc. 2011;43:590–7. https://doi.org/10.1249/MSS.0b013e3181f70bd6
- Scott RA, Moran C, Wilson RH, et al. No association between Angiotensin converting enzyme (ACE) gene variation and endurance athlete status in kenyans. Comp Biochem Physiol - Mol Integr Physiol. 2005;141:169–75. https://doi.org/10.1016/j.cbpb.2005.05.001
- Tobina T, Michishita R, Yamasawa F, et al. Association between the angiotensin I-converting enzyme gene insertion/deletion polymorphism and endurance running speed in Japanese runners. J Physiol Sci. 2010;60:325–30. https://doi.org/10.1007/s12576-010-0100-4
- 92. Collins M, Xenophontos SL, Cariolou MA, et al. The ACE gene and endurance performance during the South African Ironman triathlons. Med Sci Sports Exerc. 2004;36:1314–20.
- Amir O, Amir R, Yamin C, et al. The ACE deletion allele is associated with Israeli elite endurance athletes. Exp Physiol. 2007;92:881–6. https://doi.org/10.1113/ expphysiol.2007.038711
- Kim CH, Cho JY, Jeon JY, et al. ACE DD genotype is unfavorable to Korean short-term muscle power athletes. Int J Sports Med. 2010;31:65–71. https://d oi.org/10.1055/s-0029-1239523
- Ortiz AM, Laguarta-Val S, Varillas-Delgado D. Muscle work and its relationship with ACE and ACTN3 Polymorphisms Are Associated with the improvement of explosive strength. Genes (Basel). 2021;12. https://doi.org/10.3390/genes1 2081177
- Hall ECR, Almeida SS, Heffernan SM, et al. Genetic polymorphisms related to VO2max adaptation are Associated with Elite Rugby Union Status and competitive Marathon performance. Int J Sports Physiol Perform. 2021;16:1858– 64. https://doi.org/10.1123/ijspp.2020-0856
- Wolfarth B, Rankinen T, Mühlbauer S, et al. Association between a beta2adrenergic receptor polymorphism and elite endurance performance. Metabolism. 2007;56:1649–51. https://doi.org/10.1016/j.metabol.2007.07.006
- Fedotovskaya ON, Mustafina LJ, Popov DV, et al. A common polymorphism of the MCT1 gene and athletic performance. Int J Sports Physiol Perform. 2014;9:173–80. https://doi.org/10.1123/JJSPP.2013-0026
- Eynon N, Ruiz JR, Bishop DJ, et al. The rs12594956 polymorphism in the NRF-2 gene is associated with top-level Spanish athlete's performance status. J Sci Med Sport. 2013;16:135–9. https://doi.org/10.1016/j.jsams.2012.05.004
- 100. Yvert T, He ZH, Santiago C, et al. Acyl coenzyme a synthetase long-chain 1 (ACSL1) gene polymorphism (rs6552828) and elite endurance athletic status: a replication study. PLoS ONE. 2012;7. https://doi.org/10.1371/journal.pone.0 041268
- Santiago C, Ruiz JR, Buxens A, et al. Trp64Arg polymorphism in ADRB3 gene is associated with elite endurance performance. Br J Sports Med. 2011;45:147– 9. https://doi.org/10.1136/bjsm.2009.061366
- 102. Piscina-Viúdez XR, de la, Álvarez-Herms J, Bonilla DA, et al. Putative role of mct1 rs1049434 polymorphism in high-intensity endurance performance: concept and basis to understand possible individualization stimulus. Sports. 2021;9. https://doi.org/10.3390/sports9100143
- Saito M, Ginszt M, Massidda M, et al. Association between MCT1 T1470A polymorphism and climbing status in Polish and Japanese climbers. Biol Sport. 2021;38:229–34. https://doi.org/10.5114/BIOLSPORT.2020.98624
- 104. Lee JH, Jun HS. Role of myokines in regulating skeletal muscle mass and function. Front Physiol. 2019;10. https://doi.org/10.3389/fphys.2019.00042
- 105. Kaji H. Effects of myokines on bone. Bonekey Rep. 2016;5. https://doi.org/10.1 038/bonekey.2016;48
- Ben-Zaken S, Meckel Y, Nemet D, et al. Frequency of the MSTN Lys(K)-153Arg(R) polymorphism among track & field athletes and swimmers.

Growth Horm IGF Res. 2015;25:196–200. https://doi.org/10.1016/j.ghir.2015.0 4.001

- 107. Ferrell RE, Conte V, Lawrence EC, et al. Frequent sequence variation in the human myostatin (GDF8) gene as a marker for analysis of muscle-related phenotypes. Genomics. 1999;62:203–7.
- 108. Li X, Wang SJ, Tan SC, et al. The A55T and K153R polymorphisms of MSTN gene are associated with the strength training-induced muscle hypertrophy among Han Chinese men. J Sports Sci. 2014;32:883–91. https://doi.org/10.10 80/02640414.2013.865252
- Santiago C, Ruiz JR, Rodriguez-Romo G et al. (2011) The K153R polymorphism in the myostatin gene and Muscle Power Phenotypes in Young, non-athletic men. PLoS ONE 6.
- 110. Döring F, Onur S, Kürbitz C, et al. Single nucleotide polymorphisms in the myostatin (MSTN) and muscle creatine kinase (CKM) genes are not associated with elite endurance performance. Scand J Med Sci Sport. 2011;21:841–5. https://doi.org/10.1111/j.1600-0838.2010.01131.x
- 111. Ben-Zaken S, Meckel Y, Nemet D, Eliakim A. The combined frequency of IGF and myostatin polymorphism among track & field athletes and swimmers. Growth Horm IGF Res. 2017;32:29–32. https://doi.org/10.1016/j.ghir.2016.12.0 02
- 112. Williams AG, Dhamrait SS, Wootton PTE, et al. Bradykinin receptor gene variant and human physical performance. J Appl Physiol. 2004;96:938–42. https:/ /doi.org/10.1152/japplphysiol.00865.2003
- 113. Saunders CJ, Xenophontos SL, Cariolou MA, et al. The bradykinin β2 receptor (BDKRB2) and endothelial nitric oxide synthase 3 (NOS3) genes and endurance performance during Ironman triathlons. Hum Mol Genet. 2006;15:979– 87. https://doi.org/10.1093/hmg/ddl014
- 114. Sawczuk M, Timshina YI, Astratenkova IV, et al. The 9/+9 polymorphism of the bradykinin receptor beta 2 Gene and athlete status: a study involving two European cohorts. Hum Biol. 2013;85:741–55. https://doi.org/10.3378/027.08 5.0511
- 115. Zmijewski P, Grenda A, Leońska-Duniec A, et al. Effect of BDKRB2 gene – 9/+9 polymorphism on training improvements in competitive swimmers. J Strength Cond Res. 2016;30:665–71. https://doi.org/10.1519/JSC.000000000 001145
- 116. Grenda A, Leońska-Duniec A, Cieszczyk P, Zmijewski P. BDKRB2 gene 9/+9 polymorphism and swimming performance. Biol Sport. 2014;31:109–13. https://doi.org/10.5604/20831862.1096047
- 117. Eynon N, Meckel Y, Alves AJ, et al. Is there an interaction between BDKRB2-9/+9 and GNB3 C825T polymorphisms and elite athletic performance? Scand J Med Sci Sport. 2011;21. https://doi.org/10.1111/j.1600-0838.2010.01261.x
- Ahmad SS, Ahmad K, Lee EJ et al. (2020) Implications of insulin-like Growth Factor-1 in skeletal muscle and various diseases. Cells 9:. https://doi.org/10.33 90/cells9081773
- Ben-Zaken S, Meckel Y, Nemet D, Eliakim A. Can IGF-I polymorphism affect power and endurance athletic performance? Growth Horm IGF Res. 2013;23:175–8. https://doi.org/10.1016/j.ghir.2013.06.005
- Ben-Zaken S, Meckel Y, Nemet D, Eliakim A. IGF-I receptor 275124A > C (rs1464430) polymorphism and athletic performance. J Sci Med Sport. 2015;18:323–7. https://doi.org/10.1016/j.jsams.2014.03.007
- 121. Ben-Zaken S, Meckel Y, Nemet D, et al. Increased prevalence of the IL-6-174 C genetic polymorphism in Long Distance swimmers. J Hum Kinet. 2017;58:121–30. https://doi.org/10.1515/hukin-2017-0070
- 122. Petersen AMW, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol. 2005;98:1154–62. https://doi.org/10.1152/japplphysiol.00164.2004
- 123. Ben-Zaken S, Meckel Y, Nemet D, et al. The combined frequencies of the IL-6 G-174 C and IGFBP3 A-202 C polymorphisms among swimmers and runners. Growth Horm IGF Res. 2020;51:17–21. https://doi.org/10.1016/j.ghir.2020.01.0 02
- 124. Ahmetov II, Khakimullina AM, Popov DV, et al. [Polymorphism of the vascular endothelial growth factor gene (VEGF) and aerobic performance in athletes]. Fiziol Cheloveka. 2008;34:97–101.
- 125. Gómez-Gallego F, Ruiz JR, Buxens A, et al. The 786 T/C polymorphism of the NOS3 gene is associated with elite performance in power sports. Eur J Appl Physiol. 2009;107:565–9. https://doi.org/10.1007/s00421-009-1166-7
- 126. Eider J, Ficek K, Kaczmarczyk M, et al. Endothelial nitric oxide synthase g894t (rs1799983) gene polymorphism in Polish athletes. Cent Eur J Biol. 2014;9:260–7. https://doi.org/10.2478/s11535-013-0254-1
- 127. Zmijewski P, Cięszczyk P, Ahmetov II, et al. The NOS3 G894T (rs1799983) and – 786T/C (rs2070744) polymorphisms are associated with elite swimmer status. Biol Sport. 2018;35:313–9. https://doi.org/10.5114/biolsport.2018.76528

- Petr M, ŠťAstný P, Pecha O, et al. PPARA intron polymorphism associated with power performance in 30-s anaerobic wingate test. PLoS ONE. 2014;9. https://doi.org/10.1371/journal.pone.0107171
- 129. Tural E, Kara N, Agaoglu SA, et al. PPAR-α and PPARGC1A gene variants have strong effects on aerobic performance of Turkish elite endurance athletes. Mol Biol Rep. 2014;41:5799–804. https://doi.org/10.1007/s11033-014-3453-6
- 130. Eynon N, Meckel Y, Alves AJ, et al. Is there an interaction between PPARD T294C and PPARGC1A Gly482Ser polymorphisms and human endurance performance? Experimental physiology. Exp Physiol. 2009;94:1147–52. https:/ /doi.org/10.1113/expphysiol.2009.049668
- Maciejewska A, Sawczuk M, Cieszczyk P. Variation in the PPARα gene in Polish rowers. J Sci Med Sport. 2011;14:58–64. https://doi.org/10.1016/j.jsams.2010.0 5.006
- 132. Maciejewska-Skrendo A, Mieszkowski J, Kochanowicz A, et al. Does the PPARA Intron 7 gene variant (rs4253778) influence performance in Power/ Strength-Oriented athletes? A case-control replication study in three cohorts of European gymnasts. J Hum Kinet. 2021;79:77–85. https://doi.org/10.2478/ hukin-2020-0060
- 133. Maciejewska-Karlowska A, Hanson ED, Sawczuk M, et al. Genomic haplotype within the peroxisome proliferator-activated receptor Delta (PPARD) gene is associated with elite athletic status. Scand J Med Sci Sport. 2014;24:148–55. https://doi.org/10.1111/sms.12126
- 134. Maciejewska A, Sawczuk M, Cieszczyk P, et al. The PPARGC1A gene Gly482Ser in Polish and Russian athletes. J Sports Sci. 2012;30:101–13. https://doi.org/10 .1080/02640414.2011.623709
- 135. Ginevičienė V, Jakaitiene A, Tubelis L, Kucinskas V. Variation in the ACE, PPARGC1A and PPARA genes in Lithuanian football players. Eur J Sport Sci. 2012;14:S289–95. https://doi.org/10.1080/17461391.2012.691117
- 136. Jin HJ, Hwang IW, Kim KC, et al. Is there a relationship between PPARD T294C/ PPARGC1A Gly482Ser variations and physical endurance performance in the Korean population? Genes Genomics. 2016;38:389–95. https://doi.org/10.100 7/s13258-015-0380-4
- Proia P, Bianco A, Schiera G, et al. PPARα gene variants as predicted performance-enhancing polymorphisms in professional Italian soccer players. Open Access J Sport Med. 2014;5:273–8. https://doi.org/10.2147/OAJSM.S683 33
- Frey UH, Moebus S, Möhlenkamp S, et al. GNB3 gene 825 TT variant predicts hard coronary events in the population-based Heinz Nixdorf Recall study. Atherosclerosis. 2014;237:437–42. https://doi.org/10.1016/j.atherosclerosis.20 14.08.025
- 139. Hsiao TJ, Hwang Y, Liu CH, et al. Association of the C825T polymorphism in the GNB3 gene with obesity and metabolic phenotypes in a Taiwanese population. Genes Nutr. 2013;8:137–44. https://doi.org/10.1007/s12263-012-0 304-8
- 140. Rankinen T, Rice T, Leon AS, et al. G protein β3 polymorphism and hemodynamic and body composition phenotypes in the HERITAGE Family Study. Physiol Genomics. 2002;2002:151–7. https://doi.org/10.1152/physiolgenomic s.00102.2001
- 141. Eynon N, Oliveira J, Meckel Y, et al. The guanine nucleotide binding protein β polypeptide 3 gene C825T polymorphism is associated with elite endurance athletes. Exp Physiol. 2009;94:344–9. https://doi.org/10.1113/expphysiol.2008. 045138
- 142. Sawczuk M, Maciejewska-Karlowska A, Ciszczyk P, Leońska-Duniec A. Is GNB3 C825T polymorphism associated with elite status of Polish athletes? Biol Sport. 2014;31:21–5. https://doi.org/10.5604/20831862.1083275
- 143. Carey RM. AT 2 receptors: potential therapeutic targets for hypertension. Am J Hypertens. 2017;30:339–47. https://doi.org/10.1093/ajh/hpw121
- 144. Mustafina LJ, Naumov VA, Cieszczyk P, et al. AGTR2 gene polymorphism is associated with muscle fibre composition, athletic status and aerobic performance. Exp Physiol. 2014;99:1042–52. https://doi.org/10.1113/expphysiol.201 4.079335
- 145. Ahmetov II, Popov DV, Lyubaeva EV, et al. Association of the VEGFR2 gene His472GIn polymorphism with endurance-related phenotypes. Eur J Appl Physiol. 2009;107:95–103. https://doi.org/10.1007/s00421-009-1105-7
- 146. Ercan T, Betul Zulfinaz C, Zulfinaz CB. VEGFR2 gene polymorphism and aerobic performance in Turkish Elite endurance athletes. Int J Hum Genet. 2020;20:161–6. https://doi.org/10.31901/24566330.2020/20.03.759
- 147. Xia X, Hu Y, Xu L, Chen T. A functional promoter polymorphism of SLC2A4 is associated with aerobic endurance in a Chinese population. Eur J Sport Sci. 2014;14:53–9. https://doi.org/10.1080/17461391.2012.726652
- Homma H, Kobatake N, Sekimoto Y, et al. Ciliary neurotrophic factor receptor rs41274853 polymorphism is Associated with Weightlifting performance in

Japanese weightlifters. J Strength Cond Res. 2020;34:3037–41. https://doi.org /10.1519/JSC.000000000003750

- 149. Ruiz JR, Arteta D, Buxens A, et al. Can we identify a power-oriented polygenic profile? J Appl Physiol. 2010;108:561–6. https://doi.org/10.1152/japplphysiol.0 1242.2009
- 150. Zarebska A, Ahmetov II, Sawczyn S, et al. Association of the MTHFR 1298A > C (rs1801131) polymorphism with speed and strength sports in Russian and Polish athletes. J Sports Sci. 2014;32:375–82. https://doi.org/10.1080/0264041 4.2013.825731
- 151. Guilherme JPLF, Lancha AH. Single nucleotide polymorphisms in carnosinase genes (CNDP1 and CNDP2) are associated with power athletic status. Int J Sport Nutr Exerc Metab. 2017;27:533–42. https://doi.org/10.1123/ijsnem.201 7-0098
- 152. Maciejewska-Karlowska A, Sawczuk M, Cieszczyk P, et al. Association between the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor Gamma Gene and Strength Athlete Status. PLoS ONE. 2013;8:1–8. https:// doi.org/10.1371/journal.pone.0067172
- Ramírez JD, Álvarez-Herms J, Castañeda-Babarro A, et al. The GALNTL6 gene rs558129 polymorphism is Associated with Power Performance. J Strength Cond Res. 2020;34:3031–6. https://doi.org/10.1519/JSC.000000000003814
- Zarębska A, Sawczyn S, Kaczmarczyk M, et al. Association of RS699 (M235T) polymorphism in the AGT gene with power but not endurance athlete status. J ofStrength Cond Res. 2013;27:2898–903.
- 155. Gabbasov RT, Arkhipova AA, Borisova AV, et al. The HIF1A gene PRO582SER polymorphism in Russian strength athletes. J Strength Cond Res. 2013;27:2055–8. https://doi.org/10.1519/JSC.0b013e31827f06ae
- 156. Guilherme JPLF, Silva MS, Bertuzzi R, Lancha Junior AH. The AGTR2 rs11091046 (A > C) polymorphism and power athletic status in top-level Brazilian athletes. J Sports Sci. 2018;36:2327–32. https://doi.org/10.1080/0264 0414.2018.1455260
- 157. Heffernan SM, Stebbings GK, Kilduff LP, et al. Fat mass and obesity associated (FTO) gene influences skeletal muscle phenotypes in non-resistance trained males and elite rugby playing position. BMC Genet. 2017;18. https://doi.org/1 0.1186/s12863-017-0470-1
- 158. Guilherme JPLF, Egorova ES, Semenova EA, et al. The A-allele of the FTO gene rs9939609 polymorphism is associated with decreased proportion of slow oxidative muscle fibers and over-represented in heavier athletes. J Strength Cond Res. 2019;33:691–700. https://doi.org/10.1519/jsc.000000000003032
- 159. Zmijewski P, Leońska-Duniec A. Association between the fto a/t polymorphism and elite athlete status in caucasian swimmers. Genes (Basel). 2021;12:4–11. https://doi.org/10.3390/genes12050715
- 160. Parfenteva OI, Groth D, Scheffler C, Zaharova MF. Influence of the A/T polymorphism of the FTO gene and sport specializations on the body composition of young Russian athletes. Anthropol Anzeiger. 2019;76:401–8. https://do i.org/10.1127/anthranz/2019/0943
- 161. Eynon N, Nasibulina ES, Banting LK, et al. The FTO A/T polymorphism and Elite athletic performance: a study Involving Three groups of European athletes. PLoS ONE. 2013;8:1–6. https://doi.org/10.1371/journal.pone.0060570
- 162. Wojciechowicz B, Laguette MJN, Sawczuk M, et al. Are KIF6 and APOE polymorphisms associated with power and endurance athletes? Eur J Sport Sci. 2021;21:1283–9. https://doi.org/10.1080/17461391.2020.1817983
- Guilherme JPLF, Bigliassi M, Lancha Junior AH. Association study of SLC6A2 gene Thr99lle variant (rs1805065) with athletic status in the Brazilian population. Gene. 2019;707:53–7. https://doi.org/10.1016/j.gene.2019.05.013
- 164. Ginevičienė V, Jakaitienė A, Utkus A, et al. Ckm gene rs8111989 polymorphism and power athlete status. Genes (Basel). 2021;12. https://doi.org/10.33 90/genes12101499
- 165. Ben-Zaken S, Meckel Y, Remmel L, et al. The prevalence of IGF-I axis genetic polymorphisms among decathlon athletes. Growth Horm IGF Res. 2022;64. https://doi.org/10.1016/j.ghir.2022.101468
- 166. Ben-Zaken S, Meckel Y, Nemet D, Eliakim A. High prevalence of the IGF2 rs680 GG polymorphism among top-level sprinters and jumpers. Growth Horm IGF Res. 2017;37:26–30. https://doi.org/10.1016/j.ghir.2017.10.001
- 167. Chen S, Cai W, Duan S, et al. Association of comt polymorphisms with multiple physical activity-related injuries among university students in China. Int J Environ Res Public Health. 2021;18. https://doi.org/10.3390/ijerph182010828
- Tartar JL, Cabrera D, Knafo S, et al. The warrior COMT val/met genotype occurs in greater frequencies in mixed martial arts fighters relative to controls. J Sport Sci Med. 2020;19:38–42.
- 169. Zmijewski P, Leońska-Duniec A, Stuła A, Sawczuk M. Evaluation of the association of comt rs4680 polymorphism with swimmers' competitive performance. Genes (Basel). 2021;12. https://doi.org/10.3390/genes12101641

- 170. Ahmetov II, Naumov VA, Donnikov AE, et al. SOD2 gene polymorphism and muscle damage markers in elite athletes. Free Radic Res. 2014;48:948–55. https://doi.org/10.3109/10715762.2014.928410
- 171. Weyerstraßa J, Stewart K, Wesselius A, Zeegers M. Nine genetic polymorphisms associated with power athlete status – A Meta-analysis. J Sci Med Sport. 2018;21:213–20. https://doi.org/10.1016/j.jsams.2017.06.012
- 172. Ben-Zaken S, Eliakim A, Nemet D, et al. Increased prevalence of MnSOD genetic polymorphism in endurance and power athletes. Free Radic Res. 2013;47:1002–8. https://doi.org/10.3109/10715762.2013.838627
- 173. Liu R, Peng M, Zhang J, et al. The ALDH2 gene rs671 polymorphism is associated with cardiometabolic risk factors in east Asian population: an updated meta-analysis. Front Endocrinol (Lausanne). 2024;15. https://doi.org/10.3389/f endo.2024.1333595
- 174. Kikuchi N, Tajima T, Tamura Y, et al. The ALDH2 rs671 polymorphism is associated with athletic status and muscle strength in a Japanese population. Biol Sport. 2022;39:429–34. https://doi.org/10.5114/BIOLSPORT.2022.106151
- 175. Saito A, Saito M, Almeida KYd, et al. The Association between the ALDH2 rs671 polymorphism and athletic performance in Japanese power and strength athletes. Genes (Basel). 2022;13. https://doi.org/10.3390/genes1310 1735
- 176. Gomez-Gallego F, Santiago C, González-Freire M, et al. The C allele of the AGT Met235Thr polymorphism is associated with power sports performance. Appl Physiol Nutr Metab. 2009;34:1108–11. https://doi.org/10.1139/H09-108
- 177. Kikuchi N, Fuku N, Matsumoto R, et al. The Association between MCT1 T1470A polymorphism and power-oriented athletic performance. Int J Sports Med. 2017;38:76–80. https://doi.org/10.1055/s-0042-117113
- Voisin S, Cieszczyk P, Pushkarev VP, et al. EPAS1 gene variants are associated with sprint/power athletic performance in two cohorts of European athletes. BMC Genomics. 2014;15:1–11. https://doi.org/10.1186/1471-2164-15-382

- 179. Ginevičiene V, Jakaitiene A, Pranculis A, et al. AMPD1 rs17602729 is associated with physical performance of sprint and power in elite Lithuanian athletes. BMC Genet. 2014;15:1–9. https://doi.org/10.1186/1471-2156-15-58
- Sawczuk M, Maciejewska-Karlowska A, Cieszczyk P, et al. Association of the ADRB2 Gly16Arg and Glu27Gln polymorphisms with athlete status. J Sports Sci. 2013;31:1535–44. https://doi.org/10.1080/02640414.2013.786184
- Sawczuk M, Banting LK, Cieszczyk P, et al. MCT1 A1470T: a novel polymorphism for sprint performance? J Sci Med Sport. 2015;18:114–8. https://doi.org /10.1016/j.jsams.2013.12.008
- Miyamoto-Mikami E, Fujita Y, Murakami H, et al. CNTFR Genotype and Sprint/ power performance: Case-Control Association and Functional studies. Int J Sports Med. 2016;37:411–7. https://doi.org/10.1055/s-0035-1564257
- Voisin S, Guilherme JPFL, Yan X, et al. ACVR1B rs2854464 is associated with sprint/power athletic status in a large cohort of europeans but not brazilians. PLoS ONE. 2016;11:1–11. https://doi.org/10.1371/journal.pone.0156316
- 184. Cieszczyk P, Ostanek M, Leońska-Duniec A, et al. Distribution of the AMPD1 C34T polymorphism in Polish power-oriented athletes. J Sports Sci. 2012;30:31–5. https://doi.org/10.1080/02640414.2011.623710

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.